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ABSTRACT 
 
Prostate cancer is the second most abundant cancer with a 32% mortality rate world-wide. 
Epidemiological studies suggest an inverse relationship between risk of prostate cancer and 
intake of tomato products or higher blood levels of lycopene.   
β-carotene is centrally cleaved by carotene monoxygenase I (CMO-I) to form vitamin A 
and further metabolism results in formation of retinoic acid and other retinoids. The metabolism 
of β-carotene has been extensively studied, but very little is known about the metabolism of other 
carotenoids.  We and others have hypothesized that other acyclic carotenoids, like lycopene, are 
eccentrically cleaved by carotene monoxygenase II (CMO-II). Like retinoids, we propose that 
carotenoid metabolites produced by CMO-II enzymatic cleavage are bioactive at small 
concentrations in tissues. 
The primary aims of this proposal were to delineate tissue specific expression of CMO-I 
and CMO-II and evaluate resulting carotenoid bioaccumulation in CMO-I KO, CMO-II KO, and 
wild-type mice. Secondly, we investigated the effects of lycopene metabolties on human prostate 
cancer cells, in vitro. Thirdly, we investigated the effects of carotenoid metabolism in CMO-I 
KO, CMO-II KO, and WT mice on sex steroid hormone status. 
Lycopene preferentially accumulated in CMO-II KO mice while β-carotene preferentially 
accumulated in CMO-I KO mice. Phytofluene and phytoene accumulation was not altered by 
genotype. Together these data suggest that lycopene is eccentrically metabolized by CMO-II and 
β-carotene is centrally metabolized to retinal by CMO-I. Phytoene and phytofluene may not be 
substrates for either CMO-I or CMO-II cleavage or did not accumulate in high enough 
concentrations in the liver to induce cleavage by these enzymes. We also report that the mRNA 
expression of CMO-I and CMO-II were not altered by the carotenoid-containing diets used in 
 iii 
 
our studies. Interestingly, serum and testes testosterone were reduced and related sex steroid 
metabolizing genes were altered in CMO-I KO mice. We hypothesize that due to induced 
expression of CMO-II in the testes of CMO-I KO mice that lycopenoids are at least in part 
responsible for these effects. Lastly, we demonstrate anti-proliferative effects of the lycopene-
metabolite, apo-12’-lycopenal in androgen-dependent DU145 prostate cancer cells. 
Overall, our findings provide support for previous in vitro data to suggest that lycopene is 
metabolized by the CMO-II enzyme, in vivo. Furthermore, we have evidence to suggest that 
lycopene metabolites reduce proliferation of prostate cancer cells in vitro and may beneficially 
alter sex steroid status in mice. 
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CHAPTER 1 
LITERATURE REVIEW 
INTRODUCTION 
Prostate cancer is the second most common cancer accounting for over 192,000 new 
cases in 2009 with approximately 27,000 deaths (1).  One out of every six American men will 
experience this difficult and sometimes fatal disease in their lifetime.  Many risk factors are 
associated with prostate cancer including family history, hormone status, race, age, diet, and 
environmental factors. Diet is one of the few risk factors that may be modified.  Notably, 
consuming three to five servings of tomato products a week reduces the risk of prostate cancer in 
epidemiological studies (2).   
The estimated cumulative cost of prostate cancer treatment over five years exceeds 
$42,000 (3). Furthermore, treatment options often cause side effects with up to 43% of men 
experiencing sexual problems, 16% with urinary problems, and up to 11% of men experience 
bowel problems two years after treatment (4). With these points in mind and the fact that prostate 
cancer predominantly progresses slower than other types of cancer, dietary intervention should 
be explored as a way to prevent or reduce the progression of prostate cancer. Additionally, 
dietary modification may create a better quality of life for older men and an economic relief from 
the costs of healthcare associated with prostate cancer. 
Lycopene, which is the red pigment of tomatoes (also in tomato products) and a major 
carotenoid in human plasma and tissues, is suggested to reduce prostate cancer risk. Therefore, it 
is common to find individuals consuming lycopene in supplement form. However, at this time, 
there is not enough evidence available to definitively determine whether lycopene is wholly 
responsible for the reduced risk of prostate cancer observed when consuming tomato products. 
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Since the in vivo metabolism of tomato carotenoids is poorly understood, it is not known whether 
it is lycopene, other carotenoids or components of tomatoes, or their metabolites that influence 
prostate cancer risk.  
Tomato composition 
 Tomatoes contain significant amounts of provitamin A carotenoids, α-tocopherol, fiber, 
potassium, and folate. However, the nutrient content of tomato products varies widely depending 
upon variety, ripeness of the fruit, and the processing methods. Polyphenols, potentially 
beneficial anti-cancer compounds, are also found in tomato products, predominantly in the skin 
and seeds. Specifically, quercetin and kaempferol can be found in significant amounts (5). 
Carotenoids in tomatoes 
 Tomatoes also contain a variety of carotenoids in addition to lycopene.  While lycopene 
comprises approximately 60-64% of the total carotenoids found in tomato products, phytoene, 
phytofluene, neurosporene and γ-carotene are the next most abundant carotenoids (Figure 1.1). 
Figure 1.1: Carotenoid composition of a raw, ripe tomato (%). Adapted from (6). 
The red pigment, lycopene, is also found in lesser amounts in guava, pink grapefruit, 
papaya, passionflower fruit, and watermelon (7). Upon consumption, it accumulates in human 
Lycopene (60-64%) 
Neurosporene (7-9%) 
Phytoene (10-12%) 
Phytofluene (4-5%) 
β-Carotene (1-2%) 
γ-Carotene (10-11%) 
δ-Carotene (1-2%) 
Lutein (trace-1%) 
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and animal serum, predominantly in the liver, adrenals, testes, and prostate (8). Lycopene is a 40 
carbon atom, acyclic, open chain polyisoprenoid with 11 conjugated double bonds (9). 
 
Figure 1.2: Plant carotenoid biosynthetic pathway 
  Many carotenoids are produced in plants through a number of desaturation and cyclase 
steps (Figure 1.2). Within the plant kingdom, the colorless carotenoid, phytoene is desaturated to 
form phytofluene which through further desaturation reactions results in accumulation of 
lycopene in tomatoes. Two different isoforms of lycopene cyclase ultimately produce α-carotene 
or β-carotene. Plant based dietary sources provide most of the serum and tissue carotenoids 
found in animals. 
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All-trans lycopene is the predominant isomer found in tomatoes, but cis isomers are the 
form most commonly found in human tissues suggesting preferential absorption of cis isomers or 
isomerization within the intestinal mucosa (10). Heating and processing of tomato products 
increases the amount of cis isomers of lycopene. Cis isomers of lycopene are more soluble in bile 
acid micelles and may be preferentially integrated into chylomicrons of the small intestinal 
mucosa, thus increasing the bioavailability of lycopene (10-12). Thermal processing also 
increases bioavailability by breaking down the tomato cell matrix and decreasing food particle 
size (13).  Lastly, a tomato has a very high water weight while thermal processing of tomatoes 
causes water loss so lycopene becomes more concentrated.  
Tomato carotenoids & prostate cancer 
 In a pivotal study published in 1995 using the Health Professional Follow-up Study 
cohort, lycopene and tomato product intake were associated with a decreased risk of prostate 
cancer (2). A follow-up study of this cohort revealed that the inverse association still existed 12 
years after the original analysis (14). Another study investigated the association of the severity of 
prostate cancer and carotenoid intake and found a strong inverse association between the 
aggressive forms of cancer and lycopene intake (15). An association between plasma lycopene 
concentrations and the risk of non-familial prostate cancer was also reported (16). Lastly, a meta-
analysis of epidemiological trials found marginal effects of tomato product consumption on 
prostate cancer and this relationship was restricted to high intakes of tomatoes (17). Together, 
these studies suggest that high intakes of tomatoes or lycopene reduce the risk of aggressive, 
sporadic prostate cancer in older men. The contention that tomato products and lycopene 
consumption can reduce the risk of prostate cancer prompts further research into this relationship. 
Moreover, we find that despite the evidence indicating a beneficial effect of lycopene against 
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cancer, the mechanism(s) of action have yet to be fully elucidated. It is unclear whether lycopene 
alone, its metabolites, or other bioactive components of tomato products reduce the risk of 
prostate cancer. Additionally, it is plausible that metabolites of lycopene may be more 
biologically active than the parent compound and may be responsible for lycopene’s bioactivity. 
Carotenoid cleavage enzymes 
Carotenoid cleavage enzymes were first proposed in the 1930’s as a mechanism for 
vitamin A formation from β-carotene cleavage at the central 15,15’-double bond (18).  Three 
carotenoid cleavage oxygenases have been identified in mammals, carotene-15,15’-
monooxygenase (CMO-I), carotene-9’,10’-monooxygenase (CMO-II), and retinal pigment 
epithelium (RPE65). Many other members of this enzyme family are found in bacteria and plants 
with wide substrate specificity (19). These enzymes belong to a superfamily of iron-containing 
oxygenases which encompass a wide array of physiological roles. It has been suggested that 
RPE65, which is highly expressed in the eye of mammals, is a binding protein for all-trans-
retinyl esters but is not responsible for apo-carotenal production (20). 
CMO-I is also known in the literature as β,β-carotene 15,15’-dioxygenase, BCOI, and 
βCMOOX (21) while CMO-II is also known as β,β-carotene-9’,10’-oxygenase, BCDO2 and 
BCOII (22, 23).  Further characterization of these enzymes and their functions will help to 
clarify the appropriate nomenclature.  
The central cleavage of β-carotene to form retinal was established in the rat liver and 
intestine in the separate laboratories of Goodman and Olson in 1965 (Figure 1.3) (24, 25).  
CMO-I is a cytoplasmic enzyme that was first cloned in 2000 by Wyss and colleagues (21).  It is 
primarily found in the duodenal mucosa of mammals, but has also been found in numerous other 
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tissues (26-28). CMO-I symmetrically cleaves β-carotene to form two molecules of all-trans 
retinal. Lycopene was not cleaved by CMO-I in a model of transformed E. coli (23).   
The second carotenoid cleavage enzyme, CMO-II, is proposed to be responsible for the 
eccentric cleavage of carotenoids (Figure 1.3) (22, 23). Although eccentric cleavage products of 
β-carotene have been identified in vitro, in a model of transformed E. coli, β-carotene was not 
metabolized by CMO-II (29). Further studies investigating eccentric cleavage of β-carotene are 
necessary.  
 
Figure 1.3: Proposed metabolic pathway of tomato carotenoids in animals. 
CMO-II is expressed in many mammalian tissues including those not sensitive to vitamin 
A deficiency. Additionally, CMO-II mRNA expression can be found in tissues lacking 
expression of CMO-I. This suggests that CMO-II has a carotenoid cleavage function outside of 
vitamin A synthesis (30).  Again, using a model of E. coli expressing CMO-II, the bright red 
lycopene pigment was lost suggesting metabolic cleavage by this enzyme (23). Therefore, in vivo 
investigation of eccentric cleavage of lycopene and other carotenoids is essential to confirm this 
observation. 
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CMO-I and CMO-II are similarly distributed and expressed in the human small intestine, 
liver, eye and adrenal glands (Table 1.1) (30).  Both enzymes are also independently expressed in 
many other tissues. CMO-II appears to be less specific than CMO-I, accepting a wider range of 
substrates, including acyclic lycopene. Additionally, CMO-II has been reported to have a higher 
affinity for substrates of the cis-isomer conformation over trans-isomers (23, 31).  
Tissue CMO-I CMO-II 
Adrenals ++ ++ 
Small Intestine +++ +++ 
Liver +++ +++ 
Skeletal Muscle + +++ 
Heart - +++ 
Eye +++ +++ 
Prostate + ++ 
Pancreas +++ ++ 
Table 1.1: Relative expression of CMO-I and CMO-II in human tissues. (-) zero, (+) low, (++) 
moderate, (+++) high expression levels (23). 
The mRNA expression of carotenoid cleavage enzymes is altered with the consumption 
of lycopene in some rodent models. Recently, our laboratory measured the expression of CMO-I 
and CMO-II in F344 rats fed a lycopene-enriched diet. CMO-I expression was decreased in the 
kidney and adrenal with lycopene consumption while CMO-II was only significantly reduced in 
the kidney (32).  This reduction may be a result of feedback inhibition by lycopene and/or its 
metabolites. In another study, the expression of CMO-II mRNA increased 4-fold in the lungs of 
ferrets fed lycopene (31).  This apparent contradiction may be explained by the differential need 
 8 
 
for lycopene metabolites as necessitated by the specie or tissue. Overall, the effect of carotenoid 
consumption on the expression of carotenoid cleavage enzymes warrants investigation. 
Mutations in carotenoid cleavage enzymes 
The relative conversion of β-carotene to vitamin A in healthy individuals and the 
resulting serum or lipoprotein concentrations of carotenoids varies greatly.  This variation may 
be due to two recently reported single nucleotide polymorphisms (SNPs) existing in the human 
CMO-I gene. These SNPS are found in high frequency within the European, Chinese, and 
Japanese populations (33). A separate study in Italians found a common polymorphism near the 
CMO-I gene which lead to higher serum β-carotene and α-carotene levels (34). Lastly, in another 
independent study, a loss of function mutation in CMO-I lead to hypercarotenemia and 
hypovitaminosis A in a single patient (35).  
Several SNPs have also been identified in the coding region of the CMO-II gene (36) 
Unfortunately, no human studies have investigated carotenoid tissue or serum levels with CMO-
II gene SNPs. On the other hand, mutations in CMO-II resulted in altered carotenoid tissue 
deposition in the chicken, cow, and sheep (37-39).  
Alterations in the function of CMO-I and CMO-II, due to SNPs, may explain the varied 
effect of diet on cancer risk owing to altered production of bioactive carotenoid metabolites. 
Carotenoid metabolites 
Theoretically, cleavage of lycopene by CMO-II produces lycopenoids, more specifically, 
apo-lycopenals. Apo-lycopenals are poly-isoprenoid compounds of less than 40 carbons in length 
containing at least one aldehyde end group and are derived from the parent compound, lycopene 
(Figure 1.4). 
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Figure 1.4: Structure and molecular weight of lycopene and 3 apo-lycopenals. 
Recently, studies have identified and characterized lycopene metabolites and oxidative 
products generated in vivo. Some of these compounds demonstrate anti-cancer activity by 
inhibiting proliferation, inducing apoptosis, or enhancing cell to cell communication (40-42).  
These compounds appear to be physiologically bioactive and further identification and 
characterization of lycopene metabolites is warranted.  
A series of apo-lycopenals and short-chain carbonyl compounds were produced by in 
vitro autoxidation of lycopene (43). Among other oxidation products formed, apo-14’-lycopenal, 
apo-12’-lycopenal, apo-10’-lycopenal and apo-6’-lycopenal were identified. The authors 
suggested that tissues exposed to oxidative stress may induce lycopene metabolite formation and 
these metabolites may be essential for the biological effects of fruit and vegetable consumption 
on chronic disease risk (43).  Numerous other studies have investigated lycopene metabolite 
formation in vitro (44-46).  Caris-Veyrat and colleagues studied metabolite formation by 
potassium permanganate oxidation and oxygen catalyzed by metalloporphyrin. Eleven apo-
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lycopenals were found and characterized while a novel compound, apo-11-lycopenal, was 
identified. The authors proposed that apo-lycopenals were oxidatively cleaved from epoxides of 
lycopene. 
There are some problems associated with the use of in vitro systems for the investigation 
of carotenoids. The partial pressure of oxygen during in vitro studies is often very high in 
comparison to most tissues in the body and supraphysiological concentrations of carotenoids are 
typically used in these studies. However, these in vitro models may be important representatives 
of carotenoid cleavage in the lungs of smokers, tumors in cancer patients, or other oxidatively 
stressed conditions.  
Metabolites of lycopene have also been identified in vivo. Interestingly, in vivo 
concentrations of lycopene metabolites are of comparable biological concentrations to retinoids 
produced from β-carotene.  Table 1.2 shows the relative concentrations of metabolites from β-
carotene and lycopene reported in the literature. 
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Metabolite Animal Tissue Concentration 
Apo-6’-lycopenal Humans Plasma 0.076 ng/ml 
Apo-8’-lycopenal Rats Liver 250 ng/g 
Apo-8’-lycopenal Humans Plasma 0.142 ng/ml 
Apo-10’-lycopenal Humans Plasma 0.076 ng/ml 
Apo-12’-lycopenal Rats Liver ≥ 250 ng/g 
Apo-12’-lycopenal Humans Plasma 0.137 ng/ml 
Apo-10’-lycopenol Ferrets Lung 2-4 ng/g 
Retinal Rats Intestine 8 μg/g 
All-trans-Retinoic Acid 
AcidAcidacidAcid 
Humans Plasma 3.5 ng/ml 
ll-trans-Retinoic Acid Rats Plasma 1.2 ng/ml 
β-apo-8’-carotenal Humans Plasma 245 ng/ml 
Table 1.2: Tissue & serum concentrations of lycopene and β-carotene metabolites, in vivo (31, 
47-49) 
 Our lab has identified two apo-lycopenals in the liver of rats fed lycopene-enriched diets 
(48).  For 30-d, male F344 rats consumed a diet of 8 mg / d of lycopene, an amount equivalent to 
humans consuming 2-3 tomatoes daily (50).  A single oral dose of 0.152 mg (6,7,6’7’)- 14C 
labeled lycopene was administered 24 hours before sacrifice. Apo-8’-lycopenal and putatively 
apo-12’-lycopenal were identified while many other polar metabolites or oxidative products were 
observed, but were not identified. Lycopenoic acids may have been present in the more polar 
fractions which were not further purified. It was estimated that apo-8’-lycopenal was present at 
levels of approximately two percent of total lycopene in the liver (48).  Further analysis of the 
polar lycopene metabolites may have revealed additional short-chain apo-lycopenals produced in 
rat liver.  
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More recently, apo-6’-lycopenal, apo-8’-lycopenal, apo-10’-lycopenal, and apo-12’-
lycopenal were identified in human plasma after the consumption of tomato juice for 8 wk (47). 
Additionally, all of these metabolites were also found in low concentrations in extracts of raw 
tomato, processed tomato products, and other lycopene containing foods.  
Although a number of carotenoid cleavage products have been identified and described, 
we are only beginning to understand the biological importance of these compounds.  It is critical 
to elucidate the metabolic pathways for the production of carotenoid metabolites and to further 
clarify both their biodistribution and tissue concentration achieved following tomato carotenoid 
consumption. Ultimately, it is of great importance to determine the roles of carotenoid 
metabolites in modifying chronic disease risks. 
Lycopene’s mechanisms of action  
Many mechanisms of action have been suggested for lycopene’s reduction of prostate 
cancer risk. Fourteen in vitro studies have reported that lycopene induces apoptosis in various 
cell lines (51-64).  Two human (65, 66) and 6 animal studies (67-72) have also reported 
apoptosis induction with lycopene treatment. Numerous in vitro studies also suggest that 
lycopene induces normal cell cycle arrest while 2 animal studies report a reduction in cell cycle 
progression in both oral and prostate cancer models (70, 73). 
Gap junction communication (GJC) is essential for cells and is often lost with cancer. GJC 
is achieved by small molecular signals passing through channels that are formed by gap junction 
proteins such as connexin 43. One in vivo study found a positive association between gap 
junction communication and connexin 43 expression with lycopene consumption (74). 
Additionally, a randomized clinical trial of lycopene supplementation reported a near significant 
increase in connexin 43 protein levels, which suggests an increased gap junction communication 
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(75). Lycopene or its metabolites may be responsible for this effect. More studies are necessary 
to elucidate lycopene’s mechanisms of action in preventing or inhibiting chronic diseases. 
Sex steroids and risk of prostate cancer 
The risk of prostate cancer is strongly associated with androgen status (76, 77). Moreover 
a causal relationship is suggested in a few case reports of prostate cancer patients that previously 
used androgens as anabolic agents or medical treatment (78, 79). Additionally, administration of 
testosterone is commonly used to induce prostate cancer in rodent models (80-83). Huggins and 
Hodges first reported in 1941 that reducing testosterone levels was a potent therapeutic agent for 
patients with advanced prostate cancer (84).  
 Normal growth and function of the prostate requires androgens although higher serum 
levels of androgens, testosterone and dihydrotestosterone (DHT), are associated
 
with increased 
prostate cancer risk (15, 77).  The testes are the primary source
 
of androgens and the major serum 
androgen is testosterone. Within the prostate, testosterone
 
is converted to the more potent 
androgen DHT, primarily by 5α-reductase type II (Figure 1.5).  DHT is also found in plasma at 
about 10% of the total plasma testosterone level (85). In androgen synthesis, 17β-HSDs catalyze 
the
 
conversions between the active 17ß-hydroxysteroids
 
and less-active 17ß-ketosteroids. 17ß-
HSD
 
isozymes 1, 3, 5, and 7 convert substrates
 
to more potent androgens, whereas isozymes 2,
 
4, 
8, 10, and 11 create less active substrates and more estrogenic compounds (86). Although 17β-
HSD’s are also involved in other pathways unrelated to sex steroid metabolism, types 1, 3, and 5 
have the greatest impact on sex steroid concentrations (87). Lastly, CYP3A is involved in 
oxidizing testosterone to some of its less active metabolites in the liver (88). 
Some additional factors influence serum testosterone levels. Serum testosterone levels 
have circadian rhythms with highest levels occurring just after waking and the lowest levels 
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before going to sleep (89). Testosterone circulates in the blood bound to plasma proteins. 
Approximately 60-70% of circulating testosterone is bound to steroid hormone binding globulin 
(SHBG), 30% bound to albumin, and transcortin with 1-2% as free or unbound (90).  Free 
testosterone is the most bioavailable and is commonly what is most commonly measured 
clinically with a radioimmunoassay. Androgens bind the androgen receptor and induce 
transcription of genes. DHT has a much higher binding affinity with the androgen receptor 
compared to testosterone thus making DHT much more efficient at inducing transcription genes 
(90). Lastly, serum testosterone concentrations may not indicate tissue testosterone 
concentrations; therefore this discrepancy needs to be considered in future studies (91, 92). 
Dietary intervention studies have recently evaluated a possible
 
diet-endocrine interaction 
in prostate cancer prevention (8, 93-95).  In a phase II randomized-controlled trial, it was found 
that serum free testosterone decreased with lycopene supplementation in men with clinically 
localized prostate cancer (96). 
Previous
 
studies with rats from our laboratory suggest androgen ablation through 
castration results in altered lycopene metabolism whereby castrated rats accumulated
 
twice as 
much hepatic lycopene than intact controls even though castrated rats consumed 20% less 
lycopene (97, 98). We also reported that serum testosterone concentrations were significantly 
decreased in rats fed lycopene for 4-d (99) although longer term lycopene feeding did not alter 
serum testosterone or DHT levels (67).  Feeding lycopene for 4-d did not alter mRNA expression 
of prostatic 17β-HSD or 5α-reductase II.  The mRNA expression of hepatic CYP3A1 was 
decreased but there was no effect on its activity. Other studies reported reduced mRNA 
expression of 5α-reductase in the prostate and prostate tumor when rats were fed lycopene for 
four or eight wk (93, 94).  Additionally, another study found that Japanese males, who are less 
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likely to develop prostate cancer than Westerners, have reduced circulating levels of 5α-reducase 
metabolites (100). 
 
Figure  1.5: Schematic of steroidogenic pathway. The grey text represents enzymes and products 
that are produced in humans but are minimally produced in rodents.  Other isomers of 17β-
hydroxysteroid dehyrogenase acting upon these substrates: 
1
isomer 2;
 2
isomers 3,5; 
3
isomers 2,10; 
4
isomers 3,5,15; 
5
isomers 2,9,10; 
6
isomers 1,12; 
7
isomers 2,8,14. Adapted from Luu-The, et al 
(90). 
It is important to note that the androgen synthesis pathways in the rodent and human 
differ. The rodent 17α-hydroxylase enzyme is more active on 4-ene steroids while the human 
enzyme specificity prefers 5-ene steroids (Figure 1.5) (101-103). Therefore, rodents do not 
produce dehydroepiandrosterone (DHEA) but instead produce 4-androstenedione. Additionally, 
rodents lack expression of the 17α-hydroxylase enzyme in the adrenal gland, therefore adrenal 
sources of steroid precursors are not present in rodent serum. These differences must be 
considered when interpreting results from rodent studies for human application. 
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Overall, in vivo evidence suggests that short-term consumption of lycopene may decrease 
androgen concentrations or signaling.  This may be related to lycopene itself or to lycopene 
metabolites, but these relationships have not been investigated in depth. 
Androgens can be converted to estrogens by the enzyme, aromatase. Although androgen 
modulation has been the conventional method of prostate cancer treatment, it is apparent in 
recent literature that estrogens also play a role in prostate cancer development and treatment. 
Estrogens were classically used to suppress serum testosterone through biofeedback to the 
hypothalamus (104). Estrogen treatment has proven useful in androgen-resistant tissues 
suggesting that estrogens must work through a second mechanism (92, 105). This mechanism is 
most likely regulated by estrogen receptors. ERβ is the primary isoform found in the prostate 
although expression is lost with development of prostate cancer which parallels induced 
expression of ERα in prostate cancer cells (106). The binding of estrogens to ERα induces 
proliferation, inflammation, and development of premalignant lesions while binding to ERβ 
reduces proliferation and in general acts as a tumor suppressor (107). Therefore, it has been 
hypothesized that tissue expression levels of estrogen receptors radically affects growth, 
differentiation, malignancy and treatment of prostate cancer.  
Testosterone levels decrease with age in men while serum estrogens remain relatively 
constant; therefore it has been hypothesized that the ratio of testosterone to estrogen may be a 
key regulator of prostate cancer development (92, 104, 105, 108). Moreover, African-American 
men, who have an increased risk of developing prostate cancer, are exposed to higher circulating 
estrogen levels in utero compared to Caucasian men. This estrogen exposure may be correlated 
to increased prostate cancer risk later in life (109-111). Overall, the effects of estrogens in the 
prostate are complex and warrant further investigation.  
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To our knowledge, no studies have investigated the effects of lycopene on estrogens in 
prostate cancer cells, in vivo or in vitro. However, a couple studies have investigated this 
relationship with breast cancer incidence. Within the Women’s Health Initiative Observational 
Study, women had a reduced risk of developing ER- and progesterone-receptor positive breast 
cancers with higher intakes of lycopene or β-carotene (112). This inverse association was not 
found with other types of breast cancers suggesting that lycopene and β-carotene may inhibit 
breast cancer development through the estrogen and progesterone receptors. An in vitro study 
found that lycopene, phytoene, phytofluene, and β-carotene inhibited estrogen signaling and 
reduced proliferation of hormone-dependent MCF-7 and T47D breast cancer and ECC-1 
endometrial cancer cells (113).  
A number of anti-androgen drugs (including finasteride, dutasteride) or anti-estrogenic 
drugs (tamoxifen) have been utlized to reduce steroid-induced cancers but unfortunately adverse 
events are often seen with these regimens. Preliminary evidence suggests that lycopene 
influences androgen and estrogen signaling in cancer cells. Whether through intact lycopene or 
its metabolites, dietary intervention could provide a more sustainable, cost effective treatment 
with fewer side effects. 
 
Mouse models 
The CMO-I KO mouse was created by researchers at DSM Nutritional Products 
(Switzerland) and at the University of Freiburg (Germany) through a targeted deletion of the 
CMO-I gene in mice. We confirmed this knock-out in the liver of CMO-I KO mice. Only two 
papers have been published using CMO-I KO mice and therefore limited information is known 
about this model (114, 115).  
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It is known that CMO-I KO mice have altered lipid metabolism. CMO-I KO mice were 
reported to develop hepatic liver droplets at 3 months of age while much larger and wide spread 
lipid droplets were identified at 12 months of age (114). Collagen deposition was unaltered and 
therefore eliminated the possibility of hepatic fibrosis. At 25 wk of age, CMO-I KO mice had 
significantly increased hepatic triglycerides. The mRNA expression of hepatic fatty acid oxidase 
I (ACOX1) and stearoyl-CoA-deaturase (SCD1) was significantly increased while there was no 
effect on the expression of hepatic peroxisome proliferator-activated receptor (PPAR-α), Sterol 
Regulatory Element Binding Protein (SREBP-1c), fatty acid synthase (FAS) or retinol binding 
protein (RBP4). Within visceral adipose, the expression of PPAR-γ target genes, fatty acid 
binding protein (FABP4) and scavenger receptor (CD36), were significantly increased. 
Additionally, serum non-esterified fatty acids were significantly increased. Further analysis 
reported no alterations in serum glucose concentrations or tolerance in CMO-I KO mice. Lastly, 
glutamate pyruvate transaminase expression was significantly increased, which suggests liver 
injury (114). 
Hessel, et al. reported that CMO-I mice are prone to obesity (114). Twenty wk old female 
CMO-I KO mice were fed an obesogenic diet (30% soybean oil) which resulted in significantly 
increased serum cholesterol esters compared to control mice. Additionally, increased hepatic 
lipid droplets were reported with an increase in serum free fatty acids.  
We reported an alteration in body and organ weight and alterations in lycopene 
bioaccumulation in CMO-I KO mice.  Overall, at 22 wk of age, body weight was significantly 
increased in CMO-I KO mice compared to age-matched wild-type mice. Additionally, females 
had a significantly increased uterus weight (as a percent of body weight) compared to control 
mice (115). Furthermore, lycopene concentration was reduced in the liver, spleen, and thymus of 
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CMO-I KO mice fed lycopene-containing diets compared to wild-type mice. Interestingly, 
lycopene concentration was increased in the prostate, seminal vesicles, testes, and brain of CMO-
I KO mice compared to wild-type control mice. Additionally, the percent of cis lycopene isomers 
was greatly increased in most tissues (excluding serum and testes) of CMO-I KO mice compared 
to wild-type mice. 
The CMO-II KO mouse was created by DSM and the University of Freiburg (Germany) 
through a targeted deletion of the CMO-II gene in mice (Amengual, et al., submitted). We 
confirmed this knock-out in the liver of CMO-II KO mice. A recently submitted paper by Dr. 
von Lintig’s group at Case Western Reserve University suggests that 3-hydroxylated carotenoids 
impair mitochondrial function and induce oxidative stress in CMO-II KO mice (Amengual, et al., 
submitted). With consumption of lutein or zeaxanthin, CMO-II KO mice developed liver 
steatosis with increased triacylglycerides, induction of PPAR-γ, and reduction in the expression 
of PPAR-α. Mitochondrial respiration was reduced in CMO-II KO mice consuming these 
carotenoids and manganese superoxide dismutase, an indicator of mitochondrial dysfunction, 
was induced in hepatic mitochondria. Additionally, carotenoid consumption induced stress 
pathways (HIF-1α, p-AKT, p-MAPK) through radical oxygen species production. Impaired 
mitochondria and induction of oxidative stress in CMO-II KO mice was caused by 3-dehydro 
lutein or zeaxanthin, but not from the parent compounds alone. This suggests that CMO-II may 
play a role in protecting the mitochondria from carotenoid oxidation products. 
The transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model has been 
used extensively in prostate cancer and dietary intervention or drug therapy studies (116-121).  
The TRAMP model does not require external carcinogens as it relies on an androgen-driven and 
prostate specific expression of the large and small T antigen PB-SV40 genes (122). The large T 
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antigen abolishes p53 and Rb function while the small T antigen inhibits PP2A function (123).  
Although this system is driven by a viral oncogene, typical prostate cancer expression of IGF-1 
is observed (124, 125). The TRAMP model is initially androgen-sensitive and then develops 
androgen-insensitivity which is commonly seen in human prostate cancer (126, 127).   The 
pathobiology of the TRAMP model has also been reviewed in depth (Figure 1.6) (128). 
 
Figure 1.6: TRAMP model prostate cancer progression. 
(http://thegreenberglab.fhcrc.org/index.html) 
 
Aims of dissertation 
 The metabolism of β-carotene is widely studied, but very little is known about the 
metabolism of other tomato carotenoids including lycopene, phytofluene, and phytoene. Through 
the use of novel mouse knock-out models, we investigated carotenoid metabolism, in vivo and its 
effects on a risk factor for prostate cancer, androgen status. The effects of lycopene metabolites 
on prostate cancer proliferation were investigated, in vitro. 
The specific aims of this thesis were to:  
1. Evaluate the expression of carotenoid cleavage enzymes and resulting carotenoid 
accumulation in CMO-I KO, CMO-II KO, and wild-type mice. 
2. Evaluate the effects of lycopene and its metabolites, apo-8’-lycopenal and apo-12’-
lycopenal on the proliferation of DU145 prostate cancer cells. 
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3. Evaluate the effects of feeding lycopene or tomato powder on androgen status in mice 
lacking of the carotenoid cleavage enzymes. 
 
 
LITERATURE CITED  
1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer 
EJ, Huang L, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. 
Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data 
submission, posted to the SEER web site, 2009. .  
2. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of 
carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995;87:1767-76.  
3. Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, 
Carroll PR. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 
2007;109:518-27.  
4. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield 
TK, Litwin MS, et al. Quality of life and satisfaction with outcome among prostate-cancer 
survivors. N Engl J Med. 2008;358:1250-61.  
5. Stewart AJ, Bozonnet S, Mullen W, Jenkins GI, Lean ME, Crozier A. Occurrence of flavonols 
in tomatoes and tomato-based products. J Agric Food Chem. 2000;48:2663-9.  
6. Clinton SK. Lycopene: chemistry, biology, and implications for human health and disease. 
Nutr Rev. 1998;56:35-51.  
 22 
 
7. Mourvaki E, Gizzi S, Rossi R, Rufini S. Passionflower fruit-a "new" source of lycopene? J 
Med Food. 2005;8:104-6.  
8. Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Arch 
Biochem Biophys. 2004;430:127-34.  
9. Hadley CW, Miller EC, Schwartz SJ, Clinton SK. Tomatoes, lycopene, and prostate cancer: 
progress and promise. Exp Biol Med. 2002;227:869-80.  
10. Erdman JW, Jr. How do nutritional and hormonal status modify the bioavailability, uptake, 
and distribution of different isomers of lycopene? J Nutr. 2005;135:2046S-7S.  
11. Boileau AC, Merchen NR, Wasson K, Atkinson CA, Erdman JW, Jr. Cis-lycopene is more 
bioavailable than trans-lycopene in vitro and in vivo in lymph-cannulated ferrets. J Nutr. 
1999;129:1176-81.  
12. Gartner C, Stahl W, Sies H. Lycopene is more bioavailable from tomato paste than from 
fresh tomatoes. Am J Clin Nutr. 1997;66:116-22.  
13. Fielding JM, Rowley KG, Cooper P, O'Dea K. Increases in plasma lycopene concentration 
after consumption of tomatoes cooked with olive oil. Asia Pac J Clin Nutr. 2005;14:131-6.  
14. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato 
products, lycopene, and prostate cancer risk. J Natl Cancer Inst. 2002;94:391-8.  
 23 
 
15. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ. Lower 
prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective 
analysis. Cancer Res. 1999;59:1225-30.  
16. Wu K, Erdman JW, Jr., Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, DeGroff V, 
Willett WC, Giovannucci E. Plasma and dietary carotenoids, and the risk of prostate cancer: a 
nested case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13:260-9.  
17. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in 
the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol 
Biomarkers Prev. 2004;13:340-5.  
18. Moore T. Vitamin A and carotene: The absence of the liver oil vitamin A from carotene. VI. 
The conversion of carotene to vitamin A in vivo. Biochem J. 1930;24:692-702.  
19. Kloer DP, Ruch S, Al-Babili S, Beyer P, Schulz GE. The structure of a retinal-forming 
carotenoid oxygenase. Science. 2005;308:267-9.  
20. von Lintig J, Hessel S, Isken A, Kiefer C, Lampert JM, Voolstra O, Vogt K. Towards a better 
understanding of carotenoid metabolism in animals. Biochim Biophys Acta. 2005;1740:122-31.  
21. Wyss A, Wirtz G, Woggon W, Brugger R, Wyss M, Friedlein A, Bachmann H, Hunziker W. 
Cloning and expression of beta,beta-carotene 15,15'-dioxygenase. Biochem Biophys Res 
Commun. 2000;271:334-6.  
22. Wyss A. Carotene oxygenases: a new family of double bond cleavage enzymes. J Nutr. 
2004;134:246S-50S.  
 24 
 
23. Kiefer C, Hessel S, Lampert JM, Vogt K, Lederer MO, Breithaupt DE, von Lintig J. 
Identification and characterization of a mammalian enzyme catalyzing the asymmetric oxidative 
cleavage of provitamin A. J Biol Chem. 2001;276:14110-6.  
24. Olson JA, Hayaishi O. The enzymatic cleavage of beta-carotene into vitamin A by soluble 
enzymes of rat liver and intestine. Proc Natl Acad Sci USA. 1965;54:1364-70.  
25. Goodman DS, Huang HS. Biosynthesis of vitamin A with rat intestinal enzymes. Science. 
1965;149:879-80.  
26. Lakshman MR, Mychkovsky I, Attlesey M. Enzymatic conversion of all-trans-beta-carotene 
to retinal by a cytosolic enzyme from rabbit and rat intestinal mucosa. Proc Natl Acad Sci U S A. 
1989;86:9124-8.  
27. Nagao A, During A, Hoshino C, Terao J, Olson JA. Stoichiometric conversion of all trans-
beta-carotene to retinal by pig intestinal extract. Arch Biochem Biophys. 1996;328:57-63.  
28. Parker RS. Absorption, metabolism, and transport of carotenoids. FASEB J. 1996;10:542-51.  
29. Wang XD, Tang GW, Fox JG, Krinsky NI, Russell RM. Enzymatic conversion of beta-
carotene into beta-apo-carotenals and retinoids by human, monkey, ferret, and rat tissues. Arch 
Biochem Biophys. 1991;285:8-16.  
30. Lindqvist A, He YG, Andersson S. Cell type-specific expression of beta-carotene 9',10'-
monooxygenase in human tissues. J Histochem Cytochem. 2005;53:1403-12.  
 25 
 
31. Hu KQ, Liu C, Ernst H, Krinsky NI, Russell RM, Wang XD. The biochemical 
characterization of ferret carotene-9',10'-monooxygenase catalyzing cleavage of carotenoids in 
vitro and in vivo. J Biol Chem. 2006;281:19327-38.  
32. Zaripheh S, Nara TY, Nakamura MT, Erdman JW, Jr. Dietary lycopene downregulates 
carotenoid 15,15'-monooxygenase and PPAR-gamma in selected rat tissues. J Nutr. 
2006;136:932-8.  
33. Leung WC, Hessel S, Meplan C, Flint J, Oberhauser V, Tourniaire F, Hesketh JE, von Lintig 
J, Lietz G. Two common single nucleotide polymorphisms in the gene encoding beta-carotene 
15,15'-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J. 
2009;23:1041-53.  
34. Ferrucci L, Perry JR, Matteini A, Perola M, Tanaka T, Silander K, Rice N, Melzer D, Murray 
A, et al. Common variation in the beta-carotene 15,15'-monooxygenase 1 gene affects circulating 
levels of carotenoids: a genome-wide association study. Am J Hum Genet. 2009;84:123-33.  
35. Lindqvist A, Sharvill J, Sharvill DE, Andersson S. Loss-of-function mutation in carotenoid 
15,15'-monooxygenase identified in a patient with hypercarotenemia and hypovitaminosis A. J 
Nutr. 2007;137:2346-50.  
36. Tourniaire F, Leung W, Meplan C, Minihane A, Hessel S, von Lintig J, Flint J, Gilbert H, 
Hesketh J, Lietz G. Consequenes of genetic variations in beta-carotene cleavage enzymes in 
female volunteers. . 2008;12:57 ABSTRACT.  
 26 
 
37. Berry SD, Davis SR, Beattie EM, Thomas NL, Burrett AK, Ward HE, Stanfield AM, Biswas 
M, Ankersmit-Udy AE, et al. Mutation in bovine beta-carotene oxygenase 2 affects milk color. 
Genetics. 2009;182:923-6.  
38. Vage DI, Boman IA. A nonsense mutation in the beta-carotene oxygenase 2 (BCO2) gene is 
tightly associated with accumulation of carotenoids in adipose tissue in sheep (Ovis aries). BMC 
Genet. 2010;11:10.  
39. Eriksson J, Larson G, Gunnarsson U, Bed'hom B, Tixier-Boichard M, Stromstedt L, Wright 
D, Jungerius A, Vereijken A, et al. Identification of the yellow skin gene reveals a hybrid origin 
of the domestic chicken. PLoS Genet. 2008;4:e1000010.  
40. King TJ, Khachik F, Bortkiewicz H, Fukushima LH, Morioka S, Bertram JS. Metabolites of 
dietary carotenoids as potential cancer preventive agents. Pure and Appl Chem. 1997;69:2135-40.  
41. Zhang H, Kotake-Nara E, Ono H, Nagao A. A novel cleavage product formed by 
autoxidation of lycopene induces apoptosis in HL-60 cells. Free Radic Biol Med. 2003;35:1653-
63.  
42. Ford NA, Erdman JW, Jr. Investigation of Apo-lycopenals in DU145 and LNCaP Cells. 
FASEB J (Abstract). 2007;21:1088.  
43. Kim SJ, Nara E, Kobayashi H, Terao J, Nagao A. Formation of cleavage products by 
autoxidation of lycopene. Lipids. 2001;36:191-9.  
 27 
 
44. Khachik F, Pfander H, Traber B. Proposed mechanisms for the formation of synthetic and 
naturally occurring metabolites of lycopene in tomato products and human serum. J Agric Food 
Chem. 1998;46:4885-90.  
45. Khachik F, Steck A, Niggli U, Pfander H. Partial synthesis and structural elucidation of the 
oxidative metabolites of lycopene identified in tomato paste, tomato juice, and human serum. J 
Agric Food Chem. 1998;46:4874-84.  
46. Caris-Veyrat C, Schmid A, Carail M, Bohm V. Cleavage products of lycopene produced by 
in vitro oxidations: characterization and mechanisms of formation. J Agric Food Chem. 
2003;51:7318-25.  
47. Kopec RE, Riedl KM, Harrison EH, Curley RW,Jr, Hruszkewycz DP, Clinton SK, Schwartz 
SJ. Identification and quantification of apo-lycopenals in fruits, vegetables, and human plasma. J 
Agric Food Chem. 2010;58:3290-6.  
48. Gajic M, Zaripheh S, Sun F, Erdman JW, Jr. Apo-8'-lycopenal and apo-12'-lycopenal are 
metabolic products of lycopene in rat liver. J Nutr. 2006;136:1552-7.  
49. De Leenheer AP, Lambert WE, Claeys I. All-trans-retinoic acid: measurement of reference 
values in human serum by high performance liquid chromatography. J Lipid Res. 1982;23:1362-
7.  
50. Zaripheh S, Erdman JW, Jr. The biodistribution of a single oral dose of [14C]-lycopene in 
rats prefed either a control or lycopene-enriched diet. J Nutr. 2005;135:2212-8.  
 28 
 
51. Lordan S, O'Neill C, O'Brien NM. Effects of apigenin, lycopene and astaxanthin on 7 beta-
hydroxycholesterol-induced apoptosis and Akt phosphorylation in U937 cells. Br J Nutr. 
2008;100:287-96.  
52. Wang A, Zhang L. Effect of lycopene on proliferation and cell cycle of hormone refractory 
prostate cancer PC-3 cell line. . 2007;36:575-8.  
53. Chalabi N, Satih S, Delort L, Bignon YJ, Bernard-Gallon DJ. Expression profiling by whole-
genome microarray hybridization reveals differential gene expression in breast cancer cell lines 
after lycopene exposure. Biochim Biophys Acta. 2007;1769:124-30.  
54. Kanagaraj P, Vijayababu MR, Ravisankar B, Anbalagan J, Aruldhas MM, Arunakaran J. 
Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor 
in prostate cancer cells. J Cancer Res Clin Oncol. 2007;133:351-9.  
55. Chalabi N, Delort L, Le Corre L, Satih S, Bignon YJ, Bernard-Gallon D. Gene signature of 
breast cancer cell lines treated with lycopene. Pharmacogenomics. 2006;7:663-72.  
56. Hwang ES, Bowen PE. Effects of lycopene and tomato paste extracts on DNA and lipid 
oxidation in LNCaP human prostate cancer cells. Biofactors. 2005;23:97-105.  
57. Molnar J, Gyemant N, Mucsi I, Molnar A, Szabo M, Kortvelyesi T, Varga A, Molnar P, Toth 
G. Modulation of multidrug resistance and apoptosis of cancer cells by selected carotenoids. In 
Vivo. 2004;18:237-44.  
58. Muller K, Carpenter KL, Challis IR, Skepper JN, Arends MJ. Carotenoids induce apoptosis 
in the T-lymphoblast cell line Jurkat E6.1. Free Radic Res. 2002;36:791-802.  
 29 
 
59. Palozza P, Serini S, Boninsegna A, Bellovino D, Lucarini M, Monastra G, Gaetani S. The 
growth-inhibitory effects of tomatoes digested in vitro in colon adenocarcinoma cells occur 
through down regulation of cyclin D1, Bcl-2 and Bcl-xL. Br J Nutr. 2007;98:789-95.  
60. Salman H, Bergman M, Djaldetti M, Bessler H. Lycopene affects proliferation and apoptosis 
of four malignant cell lines. Biomed Pharmacother. 2007;61:366-9.  
61. Ivanov NI, Cowell SP, Brown P, Rennie PS, Guns ES, Cox ME. Lycopene differentially 
induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell 
lines. Clin Nutr. 2007;26:252-63.  
62. Palozza P, Sheriff A, Serini S, Boninsegna A, Maggiano N, Ranelletti FO, Calviello G, 
Cittadini A. Lycopene induces apoptosis in immortalized fibroblasts exposed to tobacco smoke 
condensate through arresting cell cycle and down-regulating cyclin D1, pAKT and pBad. 
Apoptosis. 2005;10:1445-56.  
63. Hwang ES, Bowen PE. Cell cycle arrest and induction of apoptosis by lycopene in LNCaP 
human prostate cancer cells. J Med Food. 2004;7:284-9.  
64. Hantz HL, Young LF, Martin KR. Physiologically attainable concentrations of lycopene 
induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med. 
2005;230:171-9.  
65. Bowen P, Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, Kim HS, 
Christov-Tzelkov K, van Breemen R. Tomato sauce supplementation and prostate cancer: 
 30 
 
lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med. 
2002;227:886-93.  
66. Kim HS, Bowen P, Chen L, Duncan C, Ghosh L, Sharifi R, Christov K. Effects of tomato 
sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr 
Cancer. 2003;47:40-7.  
67. Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, Erdman JW, Jr. 
Combinations of tomato and broccoli enhance antitumor activity in Dunning R3327-H prostate 
adenocarcinomas. Cancer Res. 2007;67:836-43.  
68. Liu C, Russell RM, Wang XD. Lycopene supplementation prevents smoke-induced changes 
in p53, p53 phosphorylation, cell proliferation, and apoptosis in the gastric mucosa of ferrets. J 
Nutr. 2006;136:106-11.  
69. Velmurugan B, Mani A, Nagini S. Combination of S-allylcysteine and lycopene induces 
apoptosis by modulating Bcl-2, Bax, Bim and caspases during experimental gastric 
carcinogenesis. Eur J Cancer Prev. 2005;14:387-93.  
70. Tang FY, Shih CJ, Cheng LH, Ho HJ, Chen HJ. Lycopene inhibits growth of human colon 
cancer cells via suppression of the Akt signaling pathway. Mol Nutr Food Res. 2008;52:646-54.  
71. Liu C, Lian F, Smith DE, Russell RM, Wang XD. Lycopene supplementation inhibits lung 
squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding 
protein 3 in cigarette smoke-exposed ferrets. Cancer Res. 2003;63:3138-44.  
 31 
 
72. Sengupta A, Ghosh S, Das S. Tomato and garlic can modulate azoxymethane-induced colon 
carcinogenesis in rats. Eur J Cancer Prev. 2003;12:195-200.  
73. Cheng HC, Chien H, Liao CH, Yang YY, Huang SY. Carotenoids suppress proliferating cell 
nuclear antigen and cyclin D1 expression in oral carcinogenic models. J Nutr Biochem. 
2007;18:667-75.  
74. Krutovskikh V, Asamoto M, Takasuka N, Murakoshi M, Nishino H, Tsuda H. Differential 
dose-dependent effects of alpha-, beta-carotenes and lycopene on gap-junctional intercellular 
communication in rat liver in vivo. Jpn J Cancer Res. 1997;88:1121-4.  
75. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, 
Grignon D, et al. Phase II randomized clinical trial of lycopene supplementation before radical 
prostatectomy. Cancer Epidemiol Biomarkers Prev. 2001;10:861-8.  
76. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex 
hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118-26.  
77. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a 
meta-analysis. J Clin Oncol. 2000;18:847-53.  
78. Roberts JT, Essenhigh DM. Adenocarcinoma of prostate in 40-year-old body-builder. Lancet. 
1986;2:742.  
79. Ebling DW, Ruffer J, Whittington R, Vanarsdalen K, Broderick GA, Malkowicz SB, Wein 
AJ. Development of prostate cancer after pituitary dysfunction: a report of 8 patients. Urology. 
1997;49:564-8.  
 32 
 
80. Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW, Jr., Clinton SK. Prostate 
carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, 
lycopene, or energy-restricted diets. J Natl Cancer Inst. 2003;95:1578-86.  
81. Hoover DM, Best KL, McKenney BK, Tamura RN, Neubauer BL. Experimental induction of 
neoplasia in the accessory sex organs of male Lobund-Wistar rats. Cancer Res. 1990;50:142-6.  
82. Shirai T, Tamano S, Kato T, Iwasaki S, Takahashi S, Ito N. Induction of invasive carcinomas 
in the accessory sex organs other than the ventral prostate of rats given 3,2'-dimethyl-4-
aminobiphenyl and testosterone propionate. Cancer Res. 1991;51:1264-9.  
83. Pollard M, Luckert PH. Promotional effects of testosterone and dietary fat on prostate 
carcinogenesis in genetically susceptible rats. Prostate. 1985;6:1-5.  
84. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen 
and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J 
Urol. 2002;168:9-12.  
85. Ganong WF. Review of medical physiology. 13th ed. Appleton & Lange; 1987.  
86. Soronen P, Laiti M, Torn S, Harkonen P, Patrikainen L, Li Y, Pulkka A, Kurkela R, Herrala 
A, et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol. 
2004;92:281-6.  
87. Karavolas HJ, Baedecker ML, Engel LL. Human placental 17 beta-estradiol dehydrogenase. 
V. Purification and partial characterization of the diphosphopyridine nucleotide 
(triphosphopyridine nucleotide)-linked enzyme. J Biol Chem. 1970;245:4948-52.  
 33 
 
88. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid 
metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase 
cytochrome P-450 enzyme. Arch Biochem Biophys. 1988;263:424-36.  
89. Chu LW, Zhu Y, Yu K, Zheng T, Chokkalingam AP, Stanczyk FZ, Gao YT, Hsing AW. 
Correlation between circadian gene variants and serum levels of sex steroids and insulin-like 
growth factor-I. Cancer Epidemiol Biomarkers Prev. 2008;17:3268-73.  
90. Luu-The V, Belanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. 
Best Pract Res Clin Endocrinol Metab. 2008;22:207-21.  
91. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto 
AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in 
healthy men. J Clin Endocrinol Metab. 2006;91:3850-6.  
92. Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E. Estradiol suppresses 
tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer. 
2010;10:244.  
93. Herzog A, Siler U, Spitzer V, Seifert N, Denelavas A, Hunziker PB, Hunziker W, Goralczyk 
R, Wertz K. Lycopene reduced gene expression of steroid targets and inflammatory markers in 
normal rat prostate. FASEB J. 2005;19:272-4.  
94. Siler U, Barella L, Spitzer V, Schnorr J, Lein M, Goralczyk R, Wertz K. Lycopene and 
vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB 
J. 2004;18:1019-21.  
 34 
 
95. Mossine VV, Chopra P, Mawhinney TP. Interaction of tomato lycopene and ketosamine 
against rat prostate tumorigenesis. Cancer Res. 2008;68:4384-91.  
96. Kumar NB, Besterman-Dahan K, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Krischer 
JP. Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in 
Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clin Med Urol. 
2008;1:1-14.  
97. Boileau TW, Clinton SK, Zaripheh S, Monaco MH, Donovan SM, Erdman JW, Jr. 
Testosterone and food restriction modulate hepatic lycopene isomer concentrations in male F344 
rats. J Nutr. 2001;131:1746-52.  
98. Boileau TW, Clinton SK, Erdman JW, Jr. Tissue lycopene concentrations and isomer 
patterns are affected by androgen status and dietary lycopene concentration in male F344 rats. J 
Nutr. 2000;130:1613-8.  
99. Campbell JK, Stroud CK, Nakamura MT, Lila MA, Erdman JW, Jr. Serum testosterone is 
reduced following short-term phytofluene, lycopene, or tomato powder consumption in F344 rats. 
J Nutr. 2006;136:2813-9.  
100. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE. 5-
alpha-reductase activity and risk of prostate cancer among Japanese and US white and black 
males. Lancet. 1992;339:887-9.  
101. Fevold HR, Lorence MC, McCarthy JL, Trant JM, Kagimoto M, Waterman MR, Mason JI. 
Rat P450 (17 alpha) from testis: characterization of a full-length cDNA encoding a unique 
 35 
 
steroid hydroxylase capable of catalyzing both delta 4- and delta 5-steroid-17,20-lyase reactions. 
Mol Endocrinol. 1989;3:968-75.  
102. Namiki M, Kitamura M, Buczko E, Dufau ML. Rat testis P-450 (17) alpha cDNA: the 
deduced amino acid sequence, expression and secondary structural configuration. Biochem 
Biophys Res Commun. 1988;157:705-12.  
103. Lin D, Harikrishna JA, Moore CC, Jones KL, Miller WL. Missense mutation serine 106 
proline causes 17 alpha-hydroxylase deficiency. J Biol Chem. 1991;266:15992-8.  
104. Zhu YS, Imperato-McGinley JL. 5 alpha-reductase isozymes and androgen actions in the 
prostate. Ann NY Acad Sci. 2009;1155:43-56.  
105. Ellem SJ, Risbridger GP. The dual, opposing roles of estrogen in the prostate. Ann NY 
Acad Sci. 2009;1155:174-86.  
106. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in 
prostate cancer and premalignant prostatic lesions. Am J Pathol. 1999;155:641-7.  
107. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic 
hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha 
signaling. FASEB J. 2008;22:1512-20.  
108. Ellem SJ, Risbridger GP. Aromatase and regulating the estrogen:androgen ratio in the 
prostate gland. J Steroid Biochem Mol Biol. 2010;118:246-51.  
 36 
 
109. de Jong FH, Oishi K, Hayes RB, Bogdanowicz JF, Raatgever JW, van der Maas PJ, 
Yoshida O, Schroeder FH. Peripheral hormone levels in controls and patients with prostatic 
cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. 
Cancer Res. 1991;51:3445-50.  
110. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen 
and testosterone environment of blacks and whites: potential effects on male offspring. Br J 
Cancer. 1988;57:216-8.  
111. Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new 
therapeutic candidates. J Cell Biochem. 2004;91:491-503.  
112. Cui Y, Shikany JM, Liu S, Shagufta Y, Rohan TE. Selected antioxidants and risk of 
hormone receptor-defined invasive breast cancers among postmenopausal women in the 
Women's Health Initiative Observational Study. Am J Clin Nutr. 2008;87:1009-18.  
113. Hirsch K, Atzmon A, Danilenko M, Levy J, Sharoni Y. Lycopene and other carotenoids 
inhibit estrogenic activity of 17 beta-estradiol and genistein in cancer cells. Breast Cancer Res 
Treat. 2007;104:221-30.  
114. Hessel S, Eichinger A, Isken A, Amengual J, Hunzelmann S, Hoeller U, Elste V, Hunziker 
W, Goralczyk R, et al. CMO1 Deficiency Abolishes Vitamin A Production from beta-Carotene 
and Alters Lipid Metabolism in Mice. J Biol Chem. 2007;282:33553-61.  
 37 
 
115. Lindshield BL, King JL, Wyss A, Goralczyk R, Lu CH, Ford NA, Erdman JW, Jr. 
Lycopene Biodistribution Is Altered in 15,15'-Carotenoid Monooxygenase Knockout Mice. J 
Nutr. 2008;138:2367-71.  
116. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H. 
Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. 
Cancer Res. 2000;60:5125-33.  
117. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis 
in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA. 
2001;98:10350-5.  
118. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, 
Mukhtar H. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in 
transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2004;64:3334-43.  
119. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in 
the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic 
mice (TRAMP). Cancer Res. 2001;61:6777-82.  
120. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in 
the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 2002;62:1370-6.  
121. Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 
selective inhibitors for prostate cancer chemoprevention. J Urol. 2004;171:S59,62; discussion 
S62-3.  
 38 
 
122. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, 
Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad 
Sci U S A. 1995;92:3439-43.  
123. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol. 
1996;24:502-4.  
124. Pu YS, Luo W, Lu HH, Greenberg NM, Lin SH, Gingrich JR. Differential expression of C-
CAM cell adhesion molecule in prostate carcinogenesis in a transgenic mouse model. J Urol. 
1999;162:892-6.  
125. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor 
axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate 
(TRAMP) model. Cancer Res. 1999;59:2203-9.  
126. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-
independent prostate cancer progression in the TRAMP model. Cancer Res. 1997;57:4687-91.  
127. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of 
androgen receptor gene mutations in prostate cancer. Clin Cancer Res. 2001;7:1273-81.  
128. Klein RD. The use of genetically engineered mouse models of prostate cancer for nutrition 
and cancer chemoprevention research. Mutat Res. 2005;576:111-9.  
 
 39 
 
CHAPTER II 
TOMATO CAROTENOID METABOLISM IN GENETICALLY DEFINED MICE 
DEVOID OF CMO-I OR CMO-II 
ABSTRACT 
 Two enzymes have been implicated in oxidative metabolism of carotenoids. Carotene-
15,15’-monooxygenase (CMO-I) centrally cleaves β, -carotene to form vitamin A. We 
hypothesize that carotene-9’,10’-monooxygenase (CMO-II) plays a key role in metabolism of 
non-provitamin A carotenoids, such as lycopene. We investigated carotenoid bioaccumulation in 
young adult, male wild-type (WT) mice or mice lacking either CMO-I or CMO-II. In study 1, 
mice consumed an AIN-93G diet or identical diets supplemented with 10% tomato powder, 130 
mg lycopene / kg diet (DSM, 10% lycopene beadlets) or placebo beadlets for 30-d. Lycopene 
preferentially accumulated in CMO-II KO mouse tissues while β-carotene primarily accumulated 
in CMO-I KO mouse tissues. In this study, phytofluene and phytoene did not preferentially 
accumulate in tissues of the genotypes investigated. Relative tissue mRNA expression of CMO-I 
and CMO-II in response to diet and/or genotype was evaluated. CMO-II, but not CMO-I, was 
expressed in the prostate. The expression of testicular CMO-II was significantly greater in CMO-
I KO mice compared to WT. A longer (60-d) feeding study evaluating relative carotenoid uptake 
in CMO-II KO and WT mice confirmed enhanced lycopene, but not phytofluene or phytoene, 
bioaccumulation in most CMO-II KO mouse tissues. In conclusion, CMO-II, but not CMO-I, is 
expressed in the prostate and CMO-II appears to specifically metabolize lycopene, but not the 
more saturated carotenes, phytofluene and phytoene. 
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INTRODUCTION  
Recent landmark discoveries have established that the carotenoid, β-carotene, is 
metabolized by carotene-15,15’-monooxygenase (CMO-I) through central chain cleavage to 
form vitamin A with subsequent metabolism resulting in the formation of retinoic acid and other 
retinoids (1).  The metabolism of β-carotene is widely studied, yet very little is known about the 
metabolism of many other carotenoids and the biological significance of carotenoid metabolites.  
Lycopene is the red pigment and predominant carotenoid in tomato products followed by 
phytoene, phytofluene, and β-carotene. Phytofluene and phytoene are precursors to lycopene in 
the plant biosynthetic pathway and are desaturated to form lycopene.  Accumulating studies from 
human epidemiology (2, 3), clinical studies (4-6), rodent studies (7, 8), and cells in culture have 
suggested that tomato carotenoids may have health promoting properties for a variety of acute 
and chronic disease processes.  
Our work (9) and that of others (10) has identified several metabolites and oxidative 
products of lycopene in rodent and human plasma. Interestingly, levels of lycopene metabolites 
identified in vivo are of comparable biological concentrations to retinoids suggesting that they 
may exert physiological functions (11, 12).  Studies with CMO-I knockout mice show an 
alteration in lycopene metabolism and tissue accumulation (11) and, in vitro evidence suggests 
that lycopene is metabolized primarily by carotene-9’,10’-monooxygenase (CMO-II), the 
enzyme resulting in eccentric chain cleavage of carotenoids (13).  However, at this stage, the 
metabolic production of apo-carotenals and their biological impact is poorly understood. 
We investigated the metabolism of lycopene and other tomato carotenoids in mice with 
normal genotype (wild type) (WT) and those devoid of CMO-I or CMO-II derived by knock-out 
(KO) technology.  In our first study, we evaluated tissue carotenoid accumulation and relative 
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tissue expression of CMO-I and CMO-II genes in male WT and CMO-I KO, and CMO-II KO 
mice fed diets containing tomato powder or lycopene beadlets for 30-d.  In a second 60-d study, 
we compared tissue carotenoid bioaccumulation in male and female CMO-II KO and WT mice 
fed tomato powder. 
MATERIALS & METHODS 
Mice and Diet.  
 In study 1, C57BL/6  x 129/SvJ (F1) mice (WT, n=40) were purchased from Jackson 
Laboratory (Bar Harbor, ME). Breeder pairs of Bcmo1tm1Dnp (CMO-I KO, n=4) and 
B6;129S6-Bcdo2tm1Dnp (CMO-II KO, n=4) mice were shipped to the University of Illinois 
courtesy of collaborators, Drs. Adrian Wyss at DSM Nutritional Products (Basel, Switzerland) 
and Johannes von Lintig at Case Western Reserve University. The generation of CMO-I KO 
mice was previously described (1). The generation of CMO-II KO mice is described by 
Amengual, et al. (submitted). For this study, CMO-I KO and CMO-II KO mice were bred at the 
University of Illinois animal facilities. We confirmed the genotype of these models using 
genomic DNA from mouse tail biopsies and the Sigma Extract-N-Amp Tissue PCR Kit (St. 
Louis, MO). Mice were housed in shoebox cages with free access to water and weighed every 
other day. Six to nine wk old male mice consumed an AIN-93G diet for 3 wk prior to 
randomization onto experimental diets. This study was conducted in 2 cohorts, one month apart.  
 The tomato powder diet contained 204 nmol lycopene/g diet while the lycopene beadlet 
diet provided 248 nmol lycopene/g diet. The tomato powder diet also contained 10.1 nmol 
phytoene, 2.6 nmol phytofluene, 1.3 nmol β-cryptoxanthin, and 0.8 nmol β-carotene/g diet. All 
diets were balanced for total fiber, nitrogen, and calories (Table 2.1). Additionally, vitamin A 
levels were reduced in all diets to 1500 IU retinyl palmitate per kg diet to ensure adequate 
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absorption of carotenoids without resulting in a vitamin A deficiency (11). Fresh diet was 
provided every 48 hours and new diet was made monthly. The diet was stored in the dark at 4ºC.   
 Nine- to twelve-wk old male mice were randomly assigned to one of four experimental 
diets; AIN-93G (AIN), 10% tomato powder (Futureceuticals) (TP), lycopene (DSM, 10% 
lycopene beadlet) (LYC), or placebo (DSM, 10% beadlet) (PB); n=10 per genotype/diet. Mice 
consumed the experimental diets for 30-d, ad libitum. At the conclusion of the study, mice were 
asphyxiated by CO2 and blood was collected by cardiac puncture. Brain, thymus, lungs, liver, 
spleen, duodenum mucosa, kidneys, adrenals, seminal vesicles, testes, and prostate were 
removed and snap-frozen in liquid nitrogen and then stored at -80ºC.  
 In study 2, 23-27 wk old male CMO-II KO (n= 11) and C57BL/6 (WT) mice (Harlan, 
Indianapolis, IN) (n=14) and female CMO-II KO (n= 8) and C57BL/6 (WT) (n=13) were fed a 
10% tomato powder diet (Gilroy Foods, Gilroy, CA) for 60-d, ad libitum (Table 2.1). Vitamin A 
levels were again reduced in all diets to 1500 IU retinyl palmitate per kg diet. In contrast to study 
1, the tomato powder diet was supplemented with β-carotene (beadlets, DSM) and the AIN-93G 
diet was supplemented with placebo beadlets (DSM). A different source of tomato powder was 
used in study 2 resulting in the tomato powder diet containing different amounts and proportions 
of carotenoids (17.5 nmol lycopene, 29.3 nmol phytofluene, 33.5 nmol phytoene, and 28.7 nmol 
β-carotene). All animal procedures were approved by the University of Illinois Institutional 
Animal Care and Use Committee. 
Carotenoid extraction and HPLC analysis.  
 All chemicals were purchased from Fisher Scientific (Pittsburgh, PA). Tissue and serum 
samples were extracted with hexanes as described previously with minor modifications (14). 
Briefly, 0.08g tissue (0.15g liver was used for β-carotene analysis in study 1) was added to 5 ml 
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of ethanol containing 0.01% butylated hydroxytoluene (BHT). Saturated KOH was added and 
the samples were vortexed. The samples were saponified in a waterbath at 60ºC for 30 minutes 
with vortexing every 10 minutes. Distilled water (2 ml) was added and carotenoids were 
extracted three times with 6 ml of hexanes. Serum carotenoids were extracted from 0.15 ml 
serum in 0.15 ml ethanol/BHT solution with 0.15 ml distilled water and 1.5 ml hexanes.  
 All extracts were kept on ice under yellow lights and flushed with argon to prevent 
degradation. For analysis, samples were dissolved in methyl-tert-butyl ether and injected onto a 
C30 HPLC column (4.6 x 150 mm, 3µm; YMC, Wilmington, NC) maintained at 18ºC. A 
reverse-phase HPLC-PDA method was utilized (9, 15). Individual carotenoids were identified by 
comparison of elution times to standards and absorption spectral analysis.  
Real-time PCR analysis.  
 In study 1, relative tissue expression of CMO-I and CMO-II mRNA was evaluated using 
a Trizol (Invitrogen, Carlsbad, CA) extraction as per manufacturer’s instructions followed by 
Dnase I treatment with the following modifications (New England Biolab, Ipswich, MA). 
Prostate tissue mRNA was extracted with 2 ml Trizol and testes tissue mRNA was extracted 
using 1.5 ml Trizol. mRNA concentration and quality were determined by spectrophotometry 
and agarose gel electrophoresis before synthesis of complimentary DNA by Superscript II 
Reverse Transcriptase (Invitrogen) using
 
random hexamers (Applied Biosystems, Foster City, 
CA). Primer pairs were selected to measure CMO-I (NM_021486): Forward-5'- 
ATGGAGATAATATTTGGCCAG and Reverse-5'- AACTCAGACACCACGATTC; and CMO-
II (NM_1332217): Forward-5’- GTTATCTACTTCGAGTTGGACCTGG and Reverse-5’- 
AAGCAACGCCATTCCATCA. Real-time PCR was performed using a 7900HT Fast Real-Time 
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PCR detection system (Applied
 
Biosystems) with the SYBR green fluorescence dye. Threshold 
cycle (Ct) values for the 18S gene were used as a control. 
Statistical analysis.  
 In study 1, a 3 x 4 factorial design was used with three genotypes (CMO-I KO, CMO-II 
KO, or WT) and four diets (AIN, TP, LYC, or PB). Interactions between genotype and diet were 
investigated. All parameters were analyzed by analysis of variance (2-way ANOVA) followed 
by Tukey’s post hoc analysis using SAS 9.1 (Cary, NC) with α = 0.05. The body weight analysis 
model blocked for age. When assumptions for ANOVA were violated, data were transformed by 
natural log. In study 2, a 2 x 2 factorial design was used with two genotypes (CMO-II KO or WT) 
and two sexes. Body and organ weights and carotenoid accumulation were analyzed using 
multiple linear regression. Dummy coding was used for variables and violations of model 
assumptions were corrected for using natural log transformation. Results were expressed as 
means ± SEM, unless otherwise specified.  
RESULTS 
Body and organ weight: Study 1.  
 Upon enrollment, WT mice were approximately 1 wk older than CMO-I KO and CMO-II 
KO mice; therefore, age was blocked in the final ANOVA model analysis. Diet had no effect on 
body weight, growth, or organ weight (data not shown). Body weight and change in body weight 
over the study duration was not significantly impacted by genotype (Table 2.2). However, CMO-
II KO mice had significantly heavier spleens as a percent of body weight. CMO-II KO mice also 
had significantly smaller testes and seminal vesicles while CMO-I KO mice had smaller seminal 
vesicles compared to wild-type animals. No other changes in tissue weight or body weight were 
noted (data not shown).  
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Body and organ weight: Study 2.  
 Final body weights of CMO-II KO mice were non-significantly reduced compared to WT 
mice. Additionally, some differences in organ weights of CMO-II KO mice were noted (data not 
shown). The weights of the lungs (p=0.035) and testes (p=0.0003) were increased in male CMO-
II KO mice; however the seminal vesicle (p=0.034) weight was reduced in CMO-II KO mice 
compared to WT mice. Male and female CMO-II KO mice had reduced liver weight as a percent 
of total body weight (p=0.003). Other tissue weights, as a percent of total body weight, did not 
differ by sex or genotype. 
Tissue and serum carotenoids: Study 1.  
 Carotenoids were not detected in tissues of mice consuming diets not supplemented with 
carotenoids (data not shown). CMO-II KO mice accumulated substantially higher amounts of 
lycopene in the liver (5-fold in tomato fed and 3-fold in lycopene fed) compared to WT mice.  
Higher levels of lycopene were found in the testes of both CMO-I KO and CMO-II KO mice 
(Table 2.3). Serum lycopene concentrations were higher for CMO-I KO and CMO-II KO mice 
compared to WT (Table 2.3). Overall, there was a tendency of WT and CMO-II KO mice that 
consumed the TP diet to have significantly higher serum and testicular lycopene concentrations 
compared to mice that consumed the LYC diet. 
 Levels of β-carotene in TP were quite low and resulted in marginally detectable levels in 
WT mouse tissues and serum (Table 2.4). CMO-I KO mice accumulated greater concentrations 
of β-carotene in tissues and serum compared to WT mice. CMO-II KO mice also accumulated 
more β-carotene in the liver and testes compared to WT mice, but less than CMO-I KO mice. 
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 After 30-d of feeding tomato powder, phytofluene and phytoene were not detected in 
serum or most tissues; although the liver accumulated detectable levels, concentrations did not 
differ between genotypes (Table 2.5).  
Tissue and serum carotenoids: Study 2.  
 Carotenoid biodistribution did not differ by sex (data not shown). CMO-II KO mouse 
tissues accumulated higher amounts of lycopene compared to WT mice, with the exception of 
the liver, spleen, and seminal vesicles (Table 2.6). Interestingly, compared to WT mice, CMO-II 
KO mice accumulated higher amounts of β-carotene in the liver, adrenal, kidney, and prostate 
but reduced accumulation in the lungs (Table 2.7). CMO-II KO mice in study 2 accumulated 5 
times more hepatic β-carotene, 10 times more testes β-carotene, and 90 times more serum β-
carotene compared to study 1 due primarily to the addition of β-carotene to the TP diet in study 2.  
Like study 1, phytofluene and phytoene were quantified in the liver but did not accumulate in 
detectable concentrations in other tissues (Table 2.5). Hepatic accumulation of phytofluene and 
phytoene did not differ by genotype.  
Lycopene isomers: Study 1.  
 The percentage of lycopene as cis isomers was altered in tissues of CMO-I KO and 
CMO-II KO mice fed lycopene containing diets (TP and LYC) for 30-d. CMO-II KO mice had 
significantly less hepatic 13-cis lycopene and 9-cis lycopene compared to WT mice as a percent 
of total lycopene (Table 2.8). Additionally, CMO-II KO mice accumulated less 5-cis lycopene 
and more all-trans lycopene in the testes compared to WT mice.  
mRNA Expression of CMO-I and CMO-II.  
 Of the four tissues analyzed from mice in study1, the liver had the highest relative mRNA 
expression of CMO-I while the prostate had no detectable expression of CMO-I (Figure 2.1). 
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CMO-II was most highly expressed in the mouse duodenum followed by the liver, prostate, and 
testes. There was no substantial impact of the diet on the expression of CMO-I or CMO-II in 
these tissues. A significant interaction was identified between genotype and diet (AIN, TP) for 
CMO-I and CMO-II expression in the liver. The expression of testicular CMO-II was 
significantly greater in CMO-I KO mice compared to WT mice consuming any of the four diets 
while the expression of CMO-I in the testes was significantly elevated only in CMO-II KO mice 
consuming the PB diet. In contrast, CMO-II expression was significantly reduced in the prostate 
of CMO-I KO mice compared to WT mice (LYC, TP, AIN). 
DISCUSSION  
Two separate feeding studies were designed to investigate carotenoid tissue 
bioaccumulation and the expression of carotenoid cleavage enzymes in transgenic mice lacking 
the enzymes CMO-I or CMO-II. Wild-type and transgenic mice consumed carotenoid containing 
diets or their respective controls for 30 or 60-d. We hypothesized that CMO-I and CMO-II are 
responsible for production of tomato carotenoid metabolites in animals. 
In study 1, the lycopene content in the two experimental diets was comparable (204 nmol 
for the TP vs 247 nmol for the LYC / g) although the tomato powder diet also contained other 
carotenoids, especially phytofluene and phytoene. In study 2, but not study 1, β-carotene was 
added to the tomato powder diet for a final concentration of 28.7 nmol. The tomato powder diet 
in study 2 contained much less lycopene (17.5 nmol). The level of tomato powder for these 
studies was selected to result in hepatic lycopene concentrations similar to that found in humans 
(14, 16). 
 Given that these mouse models are new, we measured body weight, change in body 
weight, and organ weights in young, adult male mice (Table 2.2).  We noted no differences in 
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body weight or change in body weight by genotype or diet; however, as a percentage of body 
weight, CMO-II KO mice had significantly enlarged spleens but smaller testes and seminal 
vesicles. CMO-I KO mice had smaller seminal vesicles as a percentage of total body weight 
compared to wild-type mice. The weights of the brain, lungs, liver, and kidneys did not differ (as 
a percentage of body weight). We previously reported CMO-I KO mice are significantly heavier 
than WT mice with resulting alterations in hepatic and serum lipids (1, 11). The mice in our 
study were young, sexually mature males while the earlier studies were conducted in 22-30 wk 
old mice. The age of the mice may be a critical factor distinguishing alterations in total body 
weight between these two studies. In study 2, we again found that seminal vesicle weight was 
reduced in CMO-II KO mice compared to WT mice. In contrast to study 1, CMO-II KO mouse 
testes were significantly larger than WT mouse testes in study 2. Furthermore, in study 2 we did 
not find enlarged spleens in CMO-II KO mice although we report liver weight, as a percentage 
of body weight, was reduced compared to WT mice. Further phenotypic characterization is 
necessary to clarify the impact of age and sex on these phenotypes. 
 CMO-II KO mice had significantly higher tissue and serum concentrations of lycopene 
compared to WT mice in the 30-d study (Table 2.3). The liver, which accumulates substantial 
quantities of lycopene compared to other tissues (7, 14, 16-18), had 3-5 times more lycopene in 
CMO-II KO mice compared to WT mice. Interestingly, CMO-I KO mice also accumulated 
somewhat greater concentrations of lycopene in the serum and testes compared to WT. Increased 
lycopene bioaccumulation in CMO-I KO mice is not explained by alterations in the expression of 
CMO-II in these mice (Figure 2.1). Instead, other enzymes may be partially responsible for 
lycopene biodistribution.  
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 In study 1, WT and CMO-II KO mice that consumed the TP diet had higher circulating 
lycopene levels than mice that consumed the LYC diet (Table 2.3). Moreover, WT mice that 
consumed the TP diet also accumulated more lycopene in the testes compared to mice that 
consumed the LYC diet. We have reported similar findings previously in rats fed lycopene-
containing diets (7). 
In our second study, CMO-II KO mice fed tomato powder for 60-d also preferentially 
accumulated lycopene in tissues compared to WT mice, with exceptions of the liver, spleen, and 
seminal vesicles (Table 2.6). The apparent inconsistency between lycopene accumulation in 
some organs in the 30-d feeding study and the 60-d feeding study may be explained by the 
choice of mouse genotype for comparison. In study 1, a mixed background WT mouse was used 
for comparison but in study 2, inbred C57BL/6 mice were used as WT mice. The apparent 
inconsistencies between these studies may also be explained by variation in lycopene content or 
total carotenoid content in the diet. Regulation of intestinal absorption may also play a role. In 
the 60-d study, the diet was supplemented with additional β-carotene. Beta-carotene 
supplementation can result in retinoic acid production that down-regulates SR-B1 in the intestine 
(19). SR-B1 is also partially responsible for lycopene uptake and circulating lycopene has been 
shown to reduce the expression of SR-B1 (20, 21).  
 Data from study 1 confirmed increased accumulation of β-carotene in CMO-I KO mouse 
tissues and serum compared to other genotypes, supporting the supposition that CMO-I is the 
primary cleavage enzyme for β-carotene (1, 11). We previously reported vitamin A production 
from β-carotene was abolished in CMO-I KO mice (1, 11). Furthermore, Paik, et al. 
demonstrated recombinant murine CMO-I efficiently converted β-carotene to vitamin A (22). 
Although not as dramatic an increase in β-carotene accumulation observed in CMO-I KO mice, 
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CMO-II KO mice also preferentially accumulated β-carotene in tissues compared to WT mice 
(Table 2.4 & 2.7). Greater accumulation of β-carotene in CMO-II KO mice is not explained by 
alterations in the expression of CMO-I (Figure 2.1). These data suggest that under some 
conditions, β-carotene may be a substrate for CMO-II cleavage, but accumulating evidence 
suggests that the primary cleavage enzyme for β-carotene is CMO-I. Further research is 
necessary to clarify the differential carotenoid substrate specificity and binding affinities for 
CMO-II. 
 CMO-II is hypothesized to cleave carotenoids at the 9’,10’ bond. Lycopene, phytofluene, 
and phytoene all have the requisite 9’,10’ double bond.  In these studies, phytofluene and 
phytoene only accumulated in detectable quantities in the liver, but hepatic concentrations did 
not differ between genotypes in either the 30-d or 60-d feeding studies (Table 2.5). These data 
suggest that lycopene is a substrate for CMO-II while apparently phytofluene and phytoene are 
not. This important finding suggests that despite almost identical structures, the reduced number 
of conjugated double bonds of phytofluene (5) and phytoene (3) compared to lycopene (11) may 
affect the affinity of the carotenoid for the CMO-II enzyme. Furthermore, carotenoid cleavage 
enzymes are highly evolutionarily conserved. Carotenoid cleavage diooxygenase (CCD1) and 
CMO-II are eccentric cleavage enzymes for plants and animals, respectively, and apparently, 
phytoene is also not a substrate for CCD1 in plants (23). However, we speculate that other 
carotenoids with a 9’,10’ bond may be substrates for CMO-II. 
 We investigated the bioaccumulation of lycopene isomers in the tissues and serum of 
CMO-I KO, CMO-II KO, and WT mice. Although foods contain a relatively low percentage of 
cis-lycopene, previous studies demonstrated that human and ferret tissues preferentially 
accumulated cis lycopene rather than all-trans lycopene (24, 25). In studies 1 and 2, most of the 
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serum and tissue lycopene was found in the cis isomer form. Moreover, the percentage of cis 
lycopene isomers was significantly altered in CMO-I KO and CMO-II KO mice in study 1, but 
not study 2 (data not shown). It is reported that cis lycopene, rather than all-trans lycopene, is a 
preferred substrate for CMO-II cleavage, in vitro (10). Therefore, we might have expected to 
find more cis lycopene in CMO-II KO mice than in WT mice. Our data is contrary to this idea. 
In fact, we generally found that CMO-II KO mice have reduced cis-lycopene isomers in tissues 
compared to WT mice.  
 Previously, we reported CMO-I KO mice accumulate more cis-lycopene isomers in 
tissues (11). While inconsistent with the results presented here, the study design differed 
considerably. The previous study fed ~22 wk old mice a high fat (16.7%) diet for 60-d. 
Consuming a high fat diet would be expected to increase lipid oxidation which may have altered 
the cis/trans lycopene isomer profiles in these mice. Overall, these data suggest that lycopene 
isomerization is altered or preferential uptake of lycopene isomers occurs in carotenoid cleavage 
knock-out mice. 
 In study 1, we investigated the expression of CMO-I and CMO-II in response to altered 
genotypes (CMO-I KO and CMO-II KO mice) and consumption of carotenoid containing diets 
(LYC and TP). Of the tissues analyzed for carotenoid cleavage enzyme mRNA expression, the 
liver had the highest relative mRNA expression of CMO-I while CMO-II was most highly 
expressed in the duodenum (Figure 2.1). Previously, we reported in rats that the relative mRNA 
expression of CMO-I was greatest in the small intestine followed by the liver, testes, and prostate 
(26). Moreover, expression of CMO-II was greatest in ventral prostate followed by the liver, 
testes, and small intestine in rats (26). Our current relative mRNA expression data are in line 
with that of two previous studies in mice and one in humans (1, 27-29).  
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 Notably, CMO-I expression was not detected in the prostate in these mouse models (any 
genotype). CMO-II was expressed in the prostate of CMO-I KO mice although its expression 
was reduced compared to WT mice. These data may imply that retinoids may not be locally 
produced in the prostate of young, adult, male mice, while lycopene metabolites may be 
produced through CMO-II cleavage. The expression of testicular CMO-II was significantly 
increased in CMO-I KO mice while the expression of CMO-I in the testes was significantly 
elevated in CMO-II KO mice compared to WT mice. This might suggest a compensatory 
regulation of expression for these enzymes in the testes. Clearly, further work regarding relative 
tissue expression, protein levels, and enzyme activity of carotenoid cleavage enzymes is 
warranted.  
Although there was no major impact of the diets alone on the transcript of CMO-I or 
CMO-II in these tissues, a significant interaction was identified between genotype and diet (AIN, 
TP) for hepatic CMO-I and CMO-II expression. Specifically, the expression of CMO-I was 
decreased in CMO-II KO mice that consumed the TP diet (compared to the AIN diet) while the 
expression of CMO-II was slightly greater in WT mice that consumed the TP diet. Furthermore, 
the expression of CMO-II was increased in CMO-I KO mice that consumed the TP diet while the 
expression of CMO-II slightly decreased in WT mice that consumed the TP diet. These 
interactions may affect the efficacy of tomato product consumption for improving health 
outcomes. 
Recently, two common single nucleotide polymorphisms (SNPs) in the human CMO-I 
gene were identified and found to reduce β-carotene metabolism by 32-69% (30). Importantly, 
these variant allele frequencies are found at up to 42% of the study population.  Additionally, one 
case study noted a loss of function mutation in the human CMO-I gene (31). SNPs for the CMO-
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II gene have not yet been investigated although mutations in the ovine, bovine and chicken 
CMO-II gene have been identified (32-34). Therefore, our results in CMO KO mice may parallel 
humans with SNPs or mutations in CMO-I and CMO-II whereby each species might respond to 
the reduced activity of one carotenoid cleavage enzyme with alterations in other protein/enzymes. 
The inverse relationship between prostate cancer incidence and tomato product 
consumption (2, 35-37) has often been attributed to lycopene. It is unknown whether lycopene, 
and/or other carotenoids or tomato components, or their metabolites primarily affect prostate 
cancer risk.  We propose that lycopene metabolites, produced by carotenoid cleavage enzymes, 
are partially responsible for this effect (37). 
 The findings in these studies support the hypothesis that lycopene, but not phytofluene or 
phytoene, is metabolized by the CMO-II enzyme. Both studies further demonstrate that the 
primary metabolism of β-carotene is by central cleavage via CMO-I. We also provide evidence 
that CMO-I KO and CMO-II KO mice have unique phenotypes. Interestingly we showed that the 
prostate lacks expression of CMO-I in all mouse genotypes studied. We also found differential 
tissue expression of CMO-I and CMO-II in mouse tissues. A separate publication will present 
additional information regarding the generation of CMO-II KO mice and the impact of CMO-II 
on the metabolism of other carotenoids (Amengual et al., submitted). Further characterization of 
these models is essential and could provide valuable insight into carotenoid metabolism and the 
impact of carotenoids on health outcomes. 
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Table 2.1. Composition of diets (g/kg diet) employed in studies of lycopene metabolism in 
CMO-I and CMO-II mutant mice. 
Ingredient  
AIN-93G
1 
(AIN)  
10% Tomato Powder 
2,3 
 (TP)  
Placebo Beadlet
4
 
(PB)  
Lycopene Beadlet
5
  
(LYC) 
Cornstarch 398 331 398 398 
Casein 200 188 200 200 
Maltodextrin 102 132 102 102 
Sucrose 100 100 100 100 
Non-nutritive cellulose 50 34 50 50 
Mineral Mix
6 
35 35 35 35 
Vitamin mix
7
  10 10 10 10 
L-cystine 3 3 3 3 
Choline bitartrate 2.5 2.5 2.5 2.5 
Soybean oil 100 65 100 100 
Tomato powder 0 100 0 0 
10% lycopene beadlets 0 0 0 0.1 
Placebo beadlets 0 0 0.1 0 
1
In study 2, the AIN diet was supplemented with (DSM) water-soluble placebo beadlets. 
2
In study 2, the tomato powder was supplemented with (DSM) water-soluble beadlets to a final 
dietary concentration of 28.7 ± 2.7 nmol β-carotene. 
3
 As measured by HPLC; the tomato powder (FutureCeuticals, Momence, IL) diet from study 1 
contained 10.1 ± 0.8 nmol phytoene, 2.6 ± 0.5 nmol phytofluene, 1.5 ± 0.3 nmol β-crytoxanthin, 
0.8 ± 0.05 nmol β-carotene, and 204 ± 30 nmol lycopene per gram diet. The tomato powder 
(Gilroy, CA) diet from study 2 contained 33.5 ± 5.6 nmol phytoene, 29.3 ± 3.4 nmol phytofluene, 
and 175 ± 13 nmol lycopene. 
4
As measured by HPLC; the placebo beadlet (DSM) diet provided 0 nmol carotenoids per gram 
diet. 
5
As measured by HPLC; the lycopene beadlet (10% DSM) diet provided 248 ± 58 nmol 
lycopene per gram diet. 
6
AIN93M-MX formulation 
7
AIN93-VX formulation with reduced vitamin A content (1500 IU retinyl palmitate / kg) 
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Table 2.2. Body (g) and organ weight (% of total body weight) in CMO-I and CMO-II mutant 
mice after 30-d of feeding (study 1)
1 
 
1
Means ± SEM; n=40 
2 
Mice were 12-15 wk of age at termination. 
* Asterisks indicate means within a row differ from WT. 
 
Table 2.3. Tissue lycopene concentrations (nmol / gram wet weight) by dietary intervention in 
CMO-I KO, CMO-II KO, and WT mice (study 1)
1 
 10% tomato powder diet  Lycopene diet 
Genotype CMO-I KO CMO-II KO Wild-type  CMO-I KO CMO-II KO Wild-type 
Liver 6.28 ± 2.46 38.1 ± 12.5*
 
7.64 ± 2.84  4.13 ± 0.82 37.0 ± 6.12*
 
12.2 ± 2.90 
  (p<0.0001)    (p<0.0001)  
Testes 1.29 ± 0.18*  1.76 ± 0.41*
 
0.74 ± 0.16  1.60 ± 0.31*
 
1.06 ± 0.13*
 
0.51 ± 0.05#
 
 (p=0.0004) (p<0.0001)   (p<0.0001) (p=0.005)  
Serum
 
0.90 ± 0.13*
 
0.89 ± 0.12*
 
0.63 ± 0.10  1.17 ± 0.24* 0.46 ± 0.05*,#
 
0.22 ± 0.04#
 
 (p=0.03) (p=0.04)   (p<0.0001) (p=0.003)  
1
Values are means ± SEM; n=6 
* Asterisks indicate means within a row differ from WT. 
# Pound sign indicates significantly different from 10% tomato powder diet of corresponding 
genotype, p<0.05. 
  Genotype  
Weight CMO-I KO CMO-II KO Wild-type 
Final body weight
2
  30.9 ± 0.62 29.9 ± 0.51 33.3 ± 0.68 
Liver 
Spleen  
3.72 ± 0.10 
0.24 ± 0.01 
3.71 ± 0.15 
0.31 ± 0.01* 
3.58 ± 0.03 
0.23 ± 0.00 
  (p<0.0001)  
Testes  0.70 ± 0.02 0.63 ± 0.01*
 
0.72 ± 0.01 
  (p<0.0001)  
Seminal vesicles  0.76 ± 0.02*
 
0.75 ± 0.02*
 
0.86 ± 0.01 
 (p=0.0007) (p=0.0001)  
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Table 2.4. Tissue β-carotene concentrations (nmol / gram wet weight) of CMO-I KO, CMO-II 
KO, and WT mice that consumed a 10% tomato powder diet for 30-d (study 1)
1
 
 Genotype 
Tissue CMO-I KO CMO-II KO Wild-type 
Liver 0.170 ± 0.061
c 
0.087 ± 0.019
b 
0.002 ± 0.001
a 
 (p<0.0001) (p=0.02)  
Testes 0.092 ± 0.018
c 
0.015 ± 0.005
b 
0.003 ± 0.002
a 
 (p<0.0001) (p=0.003) 
 
Serum  0.006 ± 0.001
b 
0.001 ± 0.000
a 2
0.000 ± 0.000
a 
 (p<0.0001)  
 
1
Data are presented as means ± SEM, n=8. Means in a row with superscripts without a common 
letter differ, p < 0.05. 
2
Below limit of detection (0.001 nmol). 
 
 
 
 
Table 2.5. Hepatic phytofluene and phytoene concentrations (nmol / gram wet weight) of CMO-
I KO, CMO-II KO, WT and WT mice that consumed a 10% tomato powder diet for 30- or 60-d 
(study 1 & 2)
1
  
 
2
30-d feeding
 
  
3
60-d feeding
 
Carotenoid CMO-I KO CMO-II KO Wild-type   CMO-II KO WT 
Phytofluene 1.57 ± 0.58 1.99 ± 0.45 1.35 ± 0.27   9.08 ± 2.12 8.98 ± 1.47 
Phytoene 4.19 ± 0.36 7.23 ± 1.26 4.82 ± 0.84   3.87 ± 0.90 3.73 ± 1.05 
1
Data are presented as means ± SEM, n=8. 
 2 
FutureCeutical tomato powder contains 2.6  nmol phytofluene and 10.1 nmol phytoene; 217 
nmol total carotenoids.  
3 
Gilroy tomato powder contains 29.3 nmol phytofluene and 33.5 nmol phytoene, 525 nmol total 
carotenoids. 
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Table 2.6. Tissue lycopene concentrations (nmol / gram wet weight) in CMO-II KO and WT 
mice fed tomato powder for 60-d (study 2)
1,2
  
 
Genotype 
Tissue CMO-II KO WT 
Liver 58.3 ± 6.90 67.5 ± 6.08 
Adrenals 9.62 ± 0.83*
 
5.97 ± 0.34 
 
(p=0.005) 
 Spleen 5.75 ± 1.37 5.88 ± 0.58 
Testes 1.44 ± 0.14*
 
0.74 ± 0.15 
 
(p=0.002) 
 Kidney 1.17 ± 0.14* 0.73 ± 0.09 
 
(p=0.02) 
 Lung 1.25 ± 0.05* 0.61 ± 0.11 
 
(p=0.0005) 
 Uterus 3.52 ± 0.68* 1.01 ± 0.13 
 
(p=0.02) 
 Serum 0.42 ± 0.05* 0.21 ± 0.02 
 
(p=0.005) 
 Prostate 1.11 ± 0.10* 0.32 ± 0.06 
 
(p=0.004) 
 Brain 0.13 ± 0.01* 0.04 ± 0.01 
 
(p<0.0001) 
 Seminal vesicles 0.04 ± 0.01 0.05 ± 0.02 
1 
Data are presented as means ± SEM; n=3-11(prostate, adrenals, and seminal vesicles were 
pooled for analysis). 
2
Gilroy tomato powder contains 175 nmol lycopene, 525 nmol total carotenoids. 
* Asterisks indicate means within a row differ from WT.  
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Table 2.7. Tissue β-carotene concentrations (nmol / gram wet weight) in CMO-II KO and WT 
mice fed tomato powder for 60-d (study 2)
1,2 
 
Genotype 
Tissue CMO-II KO WT 
Liver 0.49 ± 0.04*
 
0.25 ± 0.02 
 
(p=0.005) 
 Adrenals 0.83 ± 0.10* 0.46 ± 0.04 
 
(p=0.007) 
 Spleen 0.25 ± 0.05 0.23 ± 0.02 
Testes 0.15 ± 0.01 0.15 ± 0.00 
Kidney 0.13 ± 0.01* 0.11 ± 0.00 
 
(p=0.009) 
 Lung 0.17 ± 0.02*
 
0.29 ± 0.04 
 
(p=0.001) 
 Uterus 0.25 ± 0.02 0.20 ± 0.01 
Serum 0.09 ± 0.01 0.07 ± 0.01 
Prostate 0.09 ± 0.01* 0.05 ± 0.00 
 
(p=0.0007) 
 Brain 0.12 ± 0.02 0.15 ± 0.02 
Seminal vesicles 0.08 ± 0.02 0.06 ± 0.01 
1 
Data are presented as means ± SEM; n=3-11(prostate, adrenals, and seminal vesicles were 
pooled for analysis). 
2Gilroy tomato powder diet contained 28 nmol β-carotene as DSM water-soluble beadlets, 109 
nmol total carotenoids. 
* Asterisks indicate means within a row differ from WT. 
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Table 2.8. Tissue lycopene isomer concentration (% of total lycopene) from mice fed lycopene 
containing diets for 30-d (study 1)
1 
   Genotype  
Tissue Isomer CMO-I KO CMO-II KO Wild-type 
Liver 13-cis 24.9 ± 3.72
 
24.0 ± 0.78*
 
27.9 ± 1.93 
  (p=0.04)  
9-cis 15.1 ± 1.36 9.11 ± 0.75*
 
16.2 ± 1.45 
  (p<0.0001)  
5-cis 27.3 ± 2.46
 
26.1 ± 3.16 22.6 ± 6.54 
All-trans 32.6 ± 6.28 38.9 ± 5.66 32.3 ± 4.61 
Testes 13-cis 20.4 ± 3.23 21.1 ± 3.64 17.8 ± 1.22 
9-cis 13.9 ± 0.96
 
15.0 ± 2.32 15.7 ± 1.32 
5-cis 43.1 ± 0.88
 
31.6 ± 0.98*
 
42.2 ± 0.85 
  (p<0.0001)  
All-trans 22.7 ± 1.38 31.5 ± 3.77* 22.0 ± 0.75 
   (p=0.0001)  
Serum 13-cis 8.92 ± 0.64 13.0 ± 1.06*
 
8.40 ± 1.39 
  (p=0.009)  
9-cis 10.3 ± 0.64*
 
18.1 ± 1.39 17.2 ± 1.48 
 (p=0.004)   
5-cis 56.0 ± 2.1*
 
39.8 ± 1.62*
 
49.0 ± 1.2 
 (p=0.005) (p<0.0001)  
All-trans 25.1 ± 1.09 29.3 ± 2.78*
 
24.2 ± 1.36 
   (p=0.01)  
1 
Data are presented as means ± SEM; n=8 
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Table 2.8 (cont) 
2
The lycopene containing diets contained approximately 9% 13-cis, 6% 9-cis, 17% 5-cis, and 
68% all-trans lycopene. 
* Within a row, asterisks indicate different from WT. 
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Figure 2.1.  Relative mRNA expression of CMO-I and CMO-II in mice fed experimental diets 
for 30-d (study 1). Relative mRNA expression of CMO-I and CMO-II in (a) liver, (b) duodenum, 
(c) testes, (d) prostate. Different letters signify statistically significant. Expression was analyzed 
by ANOVA, p<0.05; n=9-11. 
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CHAPTER III 
LYCOPENE AND ITS METABOLITE, APO-12’-LYCOPENAL, REDUCE CELL 
PROLIFERATION AND ALTER CELL CYCLE PROGRESSION IN HUMAN 
PROSTATE CANCER CELLS 
ABSTRACT  
 Lycopene is associated with a reduced risk of prostate cancer. Due to difficulties with 
stability and solubility of lycopene in cell culture systems, it is difficult to elucidate the 
mechanisms of action. Moreover, lycopene may not be wholly responsible for the effects seen in 
vivo or in cell culture systems. Apo-lycopenals, whether produced by cleavage enzymes within 
the body or consumed from tomato products, can be found in human blood plasma at 
concentrations equivalent to physiological retinoid concentrations. Therefore, it is plausible that 
lycopenoids, like retinoids, are bioactive within tissues. Androgen-independent DU145 prostate 
cancer cells were treated with lycopene, apo-8’-lycopenal, or apo-12’-lycopenal. DU145 cell 
proliferation was significantly reduced by supraphysiological levels of lycopene and apo-12’-
lycopenal, in part, through significant alteration of the normal cell cycle. Levels of the gap 
junction protein, connexin 43, were unaltered by treatments while cell apoptosis rates 
significantly decreased. The present data indicates that lycopene and apo-12’-lycopenal reduce 
the proliferation of prostate cancer cells, in part, by inhibiting cells from progressing through the 
normal cell cycle. 
INTRODUCTION  
Prostate cancer is the second most abundant male cancer with over 192,000 newly 
diagnosed cases annually (1). Males born today have a 16% risk of developing prostate cancer in 
their lifetime according to the 2002-2006 SEER data (1). Diet is one of the few risk factors that 
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may be modified.  Notably, consuming three to five servings of tomato products a week reduces 
the risk of prostate cancer according to epidemiological studies (2, 3). Additionally, blood serum 
levels of lycopene, the red pigment of tomatoes, is inversely associated with prostate cancer risk 
(4). 
Lycopene is the predominant carotenoid in tomato products followed by phytoene, 
phytofluene, and β-carotene. β-carotene is metabolized by carotenoid monooxygenase I (CMO-I) 
through central chain cleavage to form vitamin A and further metabolism results in formation of 
retinoic acid and other retinoids (5). In vitro evidence suggests that lycopene is metabolized by 
carotenoid monooxygenase II (CMO-II) (6). Enzymatic cleavage by CMO-II results in eccentric 
chain cleavage of carotenoids to form aldehyde metabolites. 
In vivo studies identified and characterized tomato carotenoid metabolites and oxidative 
products (6, 7). Levels of lycopene metabolites identified in vivo are of comparable biological 
concentrations to retinoids. Kopec, et al. identified apo-6'-lycopenal, apo-8'-lycopenal, apo-10'-
lycopenal, and apo-12'-lycopenal in plasma of individuals consuming
 
tomato juice for 8 wk (8). 
These lycopene metabolites were also identified in tomato products although at much lower 
concentrations therefore dietary consumption may contribute to blood plasma apo-lycopenal 
concentrations. 
Epidemiological trials established an inverse association between the risk of prostate 
cancer and both the intake of tomato products and higher serum levels of the lycopene (2, 9). The 
inverse association is likely attributed to the proposed mechanisms of lycopene, including: 
antioxidant function, alteration in growth factors, modifying androgen status, induction of 
apoptosis, modulation of normal cell cycle progression, and enhancing gap junction 
communication. The interpretation of current literature is confused by variation of in vitro 
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techniques, culture conditions, cell types, etc. Therefore, at this time, lycopene’s mechanism of 
action is still ambiguous. We investigated proliferation, apoptosis, cell cycle progression, and 
gap junction communication of androgen-independent DU145 cells treated with lycopene or apo-
lycopenals.  
MATERIALS AND METHODS  
Cell lines and culture conditions. 
DU145 cells were purchased from ATCC (Manassas, VA) and maintained in RPMI 1640 
(Sigma-Aldrich, St. Louis, MO) without phenol red media (10% per volume FBS (fetal bovine 
serum), 2.0g/L sodium bicarbonate, 2.5g/L glucose, 2.38g/L HEPES, and 1% sodium pyruvate) 
with 5.6mg/ml amphotericin B.  Fresh media was made monthly and cells were subcultured 2-3 
times per week. The cells were maintained at 37ºC with 5% CO2.  
Preparation of carotenoids for cell culture. 
Stock solutions of 15-25μM lycopene water-soluble beadlets (5.7% pure lycopene; DSM 
Nutritional Products, Basel, Switzerland), water-soluble placebo beadlets (DSM), apo-8’-
lycopenal (BASF, Ludwigshafen, Germany), or apo-12’-lycopenal (BASF) were dissolved in 
dimethyl sulfoxide (DMSO) by sonication under yellow lights. Solubilization was confirmed 
through quick observation under a light microscope. 
Cell proliferation. 
DU145 cells were plated in 96-well plates (Sigma Aldrich) at 10,000 cells per well and were 
treated with 1, 15, or 25µM lycopene, apo-8’-lycopenal, or apo-12’-lycopenal 24 hours after 
plating.  Control wells were treated with DMSO or placebo beadlets solubilized in DMSO. The 
number of viable cells was measured 72 hours after treatment using a Promega CellTiter 96 
Aqueous Non-Radioactive Cell Proliferation Assay kit (Madison, WI). In separate experiments, 
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fresh media and lycopene were provided daily to DU145 cells (changed). For comparison, 48 
wells on the plate were incubated with lycopene for 72 hrs without replacement of media or 
lycopene treatment (unchanged). The number of viable cells was also measured using a Promega 
CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Values are the average of 
eight treated sample wells in triplicate. 
Flow cytometric analysis of apoptosis and cell cycle distribution. 
The Annexin V-FITC apoptosis Detection Kit I (BD Bioscience, San Jose, California) was used 
to the manufacturer’s instructions. Briefly, cells were split and washed with PBS two times 
before the cells were resuspended in 1x Binding Buffer. Annexin V-FITC and propidium iodide 
(PI) stains were added to the suspension and then analyzed with flow cytometry.  The protocol 
for cell cycle analysis was modified from Ueno et. al (6). Briefly, treated DU145 cells were 
trypsinized, pelleted, and resuspended in 300µL of PBS. Subsequently, 700µL of ice cold 100% 
ethanol was added a drop at a time while vortexing the cells. The cells were kept at -20ºC for less 
than 96 hours. Cells were then centrifuged for 15 minutes at 747 x g and the ethanol supernatant 
was removed. Cells were resuspended in 500μL of ice cold PBS and transferred to a 5mL 
polystyrene round-bottom tube from BD Falcon (Franklin Lakes, NJ).  Next, 12.5μL RNAse 
(20mg/ml) and 12.5μL of PI were added to the cells. Cells were incubated at 37ºC in the dark for 
30 minutes. Cells were analyzed by flow cytometry with the BD Sciences LSRII System (San 
Jose, CA) and FCS Express software from DeNovo (Los Angeles, CA) with the Multicycle AV 
add-on.  
Western blotting analysis. 
Media was aspirated off of the cells and the cells were removed from the plate with a cell scraper 
in 5mL of ice cold PBS. Cells were pelleted by centrifugation at 4ºC for 20min at 269 x g. Cells 
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were resuspended with 500μL cold CellLytic (Sigma-Aldrich) + 5µL Protease Inhibitor Cocktail 
(Sigma-Aldrich) and lysed on ice for 15min. Cells were pelleted again by centrifugation at 4ºC 
for 20 min at 12,000 x g, and the lysate was stored at -80ºC. The Bio-Rad Protein Assay Kit 
(Hercules, CA) was used per manufacturer’s instructions to create a standard protein curve for 
protein concentration. Samples were prepared for gel electrophoresis by combining sample 
Buffer (Sigma-Aldrich) and 2-Mercaptoethanol (9:1) with the cell lysate (1:1). Samples were 
then incubated at room temperature for 15min. Samples and a 5µl protein marker were loaded 
into a 12% Tris-HCl Ready Gel (Bio-Rad).  Gel electrophoresis was run for 1 hour at 105V. The 
protein sample was transferred from the gel onto an Immobilon-P Transfer Membrane from 
Millipore (Bedford, MA) at 95V for 1hr. The membrane was allowed to dry for at least one hour. 
The membrane was incubated overnight while on ice and rocking with GAPDH 1
o
 antibody 
(1:20,000) (Millipore) and Cx43 (1:125) 1
o
 antibody (Sigma) in 1% casein solution. The 
membrane was washed with TBS-T 3x’s and incubated with a mouse anti-GAPDH monoclonal 
antibody (1:20,000) (Amersham Biosciences, Sunnyvale, CA) and rabbit anti-connexin 43 
affinity isolated antibody (Invitrogen, Carlsbad, CA) for 2hrs at room temperature. The 
membrane was visualized using ECL plus (Amersham) with a Storm Image Analyzer 
(Amersham) and a photo multiplier at 650V and an emission of 520LP. Densitometry was 
analyzed using ImageQuant 5.2 (Amersham). 
Statistics. 
DU145 cell proliferation, cytotoxicity, apoptosis, and cell cycle analysis were analyzed by one-
way ANOVA followed by Tukey’s post hoc test (SAS 9.1, Carey, NC). A p-value of ≤0.05 was 
considered significant. Proliferation data were log transformed to meet statistical test 
assumptions.  
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RESULTS  
Effects of lycopene treatment on proliferation.   
 DU145 cells were treated with 1, 15, or 25μM lycopene or vehicle alone for 72 hours. 
DU145 cell proliferation was significantly reduced by 10%  and 19% with 15μM and 25μM 
lycopene, respectively (ANOVA, p<0.05, n=3) (Fig 3.1a). 
Lycopene treatment reduces apoptosis  and inhibits cell-cycle progression.   
 Flow cytometry was used to assess apoptosis and cell cycle distribution after DU145 cells 
were treated with various doses of lycopene. Incubating cells with lycopene for 72 hours 
significantly reduced apoptosis of cells at all concentrations. Figure 3.1b shows all treatments 
resulted in a 92-93% reduction in apoptosis rates compared to control cells (ANOVA, p<0.05, 
n=9).  Lycopene at 1, 15, and 25µM caused a significant reduction in the total number of cells in 
the S phase (ANOVA, p<0.05, n=9) (Fig 3.1c). Neither the G1 nor G2/M phases were 
significantly altered with lycopene treatment. 
Lycopene treatment does not affect the levels of gap junction protein, Cx43.  
 DU145 cells were treated with 0-25μM lycopene for 72 hours and the cell lysates were 
analyzed by Western blot for protein levels of Cx43, normalized to GAPDH. Lycopene treatment 
did not affect the protein level of Cx43 (n=4) (Fig 3.2a). 
Not replacing media and lycopene treatment daily most greatly affects proliferation.  
 Cells were treated with lycopene (10µM)  for 72 hours. Fresh media and lycopene were 
provided daily to half of the cells and compared to cells treated with unchanged media and 
lycopene treatment. Figure 3.3 shows a 23% inhibition of DU145 cells when media was 
unchanged during the 72 hr incubation period while only a 4% inhibition was found when media 
and treatment were replaced daily (ANOVA, p<0.05, n=3). 
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Apo-12’-lycopenal, but not apo-8’-lycopenal reduces proliferation.   
 Apo-12’-lycopenal (1-25µM) reduced proliferation of androgen-independent DU145 
cells in a dose-dependent manner (ANOVA, p<0.05, n=3).  Conversely, apo-8’-lycopenal did not 
affect proliferation of this prostate cancer cell line (Fig 3.4a). Apo-12’-lycopenal (25µM) 
significantly inhibited proliferation by 7%. 
Apo-12’-lycopenal treatment reduces apoptosis and inhibits cell-cycle progression. 
 Apoptosis and cell cycle distribution of DU145 cells were analyzed by flow cytometry 
after treatment with 0-25µM of apo-12’-lycopenal for 72 hours. Incubating cells with 1, 15, or 
25µM apo-12’-lycopenal significantly reduced apoptosis of cells (ANOVA, p<0.05, n=9). All 3 
treatments resulted in an 87-96% reduction in apoptosis rates compared to control cells (Fig 
3.4b).  Apo-12’-lycopenal treatment also resulted in a significant reduction in the total number of 
cells in the S phase at all concentrations (ANOVA, p<0.05, n=9)(Fig 3.4c). No significant 
changes in the number of cells accumulating in the G1 or G2/M phases were found. 
Apo-12’-lycopenal treatment does not affect gap junction protein, Cx43, levels.   
 DU145 cells were treated with varying concentrations of apo-12’-lycopenal and the cell 
lysate was analyzed by Western blot for protein level of Cx43 and normalized to GAPDH. Apo-
12’-lycopenal treatment did not affect the levels of the Cx43 protein at any concentration (Fig. 
3.2b).  
DISCUSSION  
 Numerous studies report lycopene reduces proliferation of prostate cancer cells, in vitro 
(10-18).  Due to variability in cell lines, culture conditions, solvents used to deliver lycopene, 
and the source of lycopene, the mechanisms of reduced proliferation are still open to further 
investigation.  We investigated several of these mechanisms in vitro. This study provides 
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evidence that at least one lycopene metabolite, apo-12’-lycopenal, is bioactive and may 
contribute to reduced prostate cancer risk as previously observed with consuming lycopene-
containing diets.  
 The investigation of carotenoids in cell culture conditions has proved difficult and 
standard methods have not been developed. Lycopene is an excellent antioxidant; therefore it 
suffers considerable degradation and isomerization under cell culture conditions (19). Vitamins 
C and E have been used to protect lycopene in these conditions, but inclusion of these 
antioxidants complicates outcomes (20-22). Another issue faced in biological and artificial 
systems is carotenoid aggregation or stacking (19). All-trans lycopene is a linear hydrocarbon 
and in hydrophobic media lycopene can quickly form aggregates of closely stacked lycopene 
monomers in parallel sheets that result in reduced contact with the cells and the culture 
environment compared to monomers. Because lycopene is not soluble in cell culture media it 
must be solubilized. Many solvents including tetrahydrofuran, Tween, and dimethylsufloxide 
have been used in addition to mammalian serum and micelles. Each lycopene delivery method 
has its advantages and limitations related to crystallization, commercial availability, 
solubilization ability, toxicity, and labor time. For example, THF readily solubilizes lycopene but 
possesses a moderate Materials Safety Data Sheet hazard rating and can form peroxides at 
greater than 1% v/v ratio. Lastly, duration of lycopene treatment varies widely within the 
literature. Cells treated with lycopene from 12 hours to 7-d with increased time significantly 
reducing proliferation. Overall, in vitro results investigating lycopene vary considerably most 
likely due to variation in culturing techniques and care taken to avoid isomerization, oxidations, 
and stacking. 
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 Our study shows that lycopene significantly reduces proliferation of DU145 cells at 
supra-physiological concentrations (15 and 25μM).  However, when the physiological 
concentration of lycopene (>2μM) (23) was investigated, we do not see reduced proliferation.  
To our knowledge, the effects of lycopene on the proliferation of DU145 cells have been 
investigated in 3 previous studies.  Two of those studies demonstrate that supra-physiological 
doses reduced proliferation while one found no changes in proliferation with physiological 
concentrations (15, 18, 24). Therefore, the proliferation results of this study are in alignment with 
previous in vitro findings. 
 Results from in vivo and in vitro studies suggest that lycopene induces apoptosis of 
cancer cells (12, 13, 15, 23, 25). We found no evidence to support these findings in the current 
study but rather surprisingly found that lycopene, at all concentrations investigated, significantly 
reduced apoptosis compared to control cells. Our data matches previous findings in lymphocytes 
and macrophages but disagrees with previous findings in prostate cancer cells (26-28). 
Disagreement between our findings and previous studies may be due to pro-oxidant effects 
caused by supra-physiological lycopene concentrations in cell culture conditions. 
 We also investigated cell-cycle regulation, another commonly-reported mechanism of 
action of lycopene.  The cell cycle of DU145 cells was altered with 1-25µM lycopene resulting 
in cells accumulating in the G1 and G2/M phase. Moreover, significantly fewer DU145 cells 
accumulating in the S phase suggests that the cancer cells were not progressing through the cell 
cycle normally. Therefore, in these experiments, cell cycle arrest contributes, in part, to reduced 
proliferation of DU145 cells by lycopene treatment. Our findings corroborate other reports which 
indicate lycopene inhibits normal cell cycle progression of prostate cancer cells (12, 15, 25). 
Tang, et al. reported DU145 cells treated with 16µM and 32µM lycopene reduced the 
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accumulation of cells in the S phase by approximately 50% (15), which is similar to our current 
findings. Additionally, as shown in our study using similar concentrations, increasing lycopene 
concentration from 16µM to 32µM did not further reduce cells accumulating in the S phase. 
Moreover, Tang, et al. report significant increases in DU145 cells accumulating in the G2/M 
phase which supports the non-significant trend we demonstrate in this study. Altogether, we and 
others report that lycopene alters cell cycle progression in prostate cancer cells. 
 Lastly, one of the earliest suggested mechanisms of action of lycopene is enhancement of 
GJC through increased concentrations of the connexin 43 protein. Research consistently 
demonstrates the importance of GJC in maintaining normal cell function (29). We did not find an 
increase in the protein levels of Cx43 with lycopene treatment in DU145 cells. Cancer cells often 
express very low levels of Cx43 protein; therefore, very little protein was detected in the control 
cells. Overall, we found no change in the protein levels of Cx43 in vitro with lycopene. The 
apparent contradiction in our DU145 cell results and those of others may be due to the 
malignancy of the cells. King and Bertram suggest that GJC may not be restored by carotenoids 
in cell lines containing multiple mutations (29). They further state that only forced expression of 
connexins, gene transfer, or hypomethylation may overcome loss of expression of the connexin 
genes. Further research in this area is warranted. On the other hand, due to the short half-life of 
Cx43 (1.5-5 hours), functional assays may not be appropriate and may further complicate results 
in the literature (30). 
Unfortunately, due to high temperatures and presence of oxygen, lycopene rapidly 
oxidizes and degrades in cell culture systems making it difficult to interpret results of in vitro 
studies with lycopene. For this reason, we compared proliferation of DU145 cells treated with 
fresh cell culture medium and treatment daily (changed) to that of cells treated with lycopene 
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without replacing medium or treatment (unchanged) during the 72 hour incubation. Interestingly, 
proliferation of DU145 cells was most significantly reduced when culture media and treatment 
were unchanged for 72 hours.  We interpret this to suggest that oxidative products of lycopene 
produced in vitro and/or metabolic products of lycopene produced in DU145 cells reduce the 
proliferation of prostate cancer cells. Subsequently, to rule out cytotoxicity as a factor, we 
performed CytoTox 96 Non-Radioactive Cytotoxicity Assays (Promega, Madison, WI). No 
significant increase in cytotoxicity resulted with up to 25μM lycopene treatment compared to the 
control cells. Given our findings, we propose that oxidative products or lycopene metabolites are 
bioactive and reduce DU145 cell proliferation of prostate cancer cells, alone, or in combination, 
with lycopene. 
We investigated the effects of two known lycopene metabolites, apo-8’-lycopenal and 
apo-12’-lycopenal, on the proliferation of DU145 cells (7). Both metabolites have been identified 
as metabolic products of lycopene that was exposed to cell culture conditions for 72 hours (31). 
Moreover, our lab previously identified apo-8’-lycopenal and potentially apo-12’-lycopenal in 
the liver of rats fed lycopene containing diets (7). Apo-12’-lycopenal significantly reduces 
proliferation of DU145 cells at 15μM and 25μM, while apo-8’-lycopenal has no effect on 
proliferation. Similarly, others report that lycopene metabolites reduced proliferation in several 
cell types (32-36). For instance, an apo-lycopenoid, apo-10’-lycopenoic acid (3-10µM), reduced 
proliferation of non-small-cell lung cancer cells and 2 bronchial epithelial cell types (36). 
We further investigated the mechanisms of reduced DU145 proliferation by apo-12’-
lycopenal.  Results of other studies suggest lycopene metabolites have antioxidant properties, 
mediate retinoid signaling through RAR-β,  induce phase II enzymes, and interfere with insulin-
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like growth factors (32, 36-39). We analyzed apoptosis and cell cycle progression by flow 
cytometry and GJC as indicated by protein levels of Cx43.  
As similarly seen with lycopene, apo-12’-lycopenal significantly reduced apoptosis and 
inhibited normal cell cycle progression. Cells treated with apo-12’-lycopenal accumulated in the 
G1 and G2/M phase while significantly fewer DU145 cells accumulated in the S phase. Therefore, 
apo-12’-lycopenal appears to reduce proliferation of DU145 cells, in part, through cell cycle 
arrest. Few other studies have investigated the effects of lycopene metabolites on apoptosis or 
cell cycle progression. Zhang, et al. indicate the oxidative lycopene metabolite, (E,E,E)-4—
methyl-8-oxo-2,4,6-nonatrienal, induced apoptosis and inhibited normal cell cycle progression in 
human promyelocytic leukemia cells (HL-60) (35). Other studies suggest that lycopene 
metabolites have no effect on apoptosis. Lian, et al. reported apo-10’-lycopenoic acid reduced 
proliferation of NHBE normal human bronchial epithelial
 
cells, BEAS-2B-immortalized normal 
bronchial epithelial cells
 
and A549 non-small cell lung cancer cells, altered cell cycle 
progression, but did not alter apoptosis (36). Our study adds to the in vitro literature by 
demonstrating that apo-12’-lycopenal reduces apoptosis of DU145 cells. Overall, apo-12’-
lycopenal, in part, reduces proliferation of DU145 cells through disruption of normal cell cycle 
progression and our results are supported by other in vitro lycopene metabolite studies. 
Lastly, we measured Cx43 protein levels by Western blot as an indicator of GJC. Two 
papers report that longer incubation with carotenoids (3-7 d) is required to induce the expression 
of Cx43 compared to retinoids. The authors hypothesize that carotenoids must first be 
oxidatively or metabolically cleaved before significant increases in GJC can be observed (40, 41). 
Therefore, we proposed that carotenoid metabolites would have a greater capacity to increase 
GJC, via expression of Cx43, than does the parent carotenoid compound.  Other studies showed 
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that lycopene metabolites effectively increased Cx43 protein levels in rat liver epithelial WB-
F344 cells, human keratinocytes, and human fetal skin fibroblasts (HFFF2) (42-44). However, 
apo-12’-lycopenal treatment did not alter the protein levels of Cx43 in DU145 cells. Apparent 
conflict in results between our study and the previously reported study may be due to species, 
tissue, or lycopene metabolite. However, we are the first to report that the lycopene metabolite, 
apo-12’-lycopenal, does not affect protein levels of Cx43 in DU145 cells. 
 In summary, we found that lycopene, at supra-physiological concentrations, reduces 
proliferation of DU145 cells, in part, through alteration in normal cell cycle progression. 
Lycopene did not alter Cx43 protein levels in DU145 cells. This suggests that lycopene does not 
reduce prostate cancer risk by enhancing GJC through Cx43.  Our results suggest that unknown 
lycopene oxidative or metabolic products reduce proliferation of DU145 cells more than the 
parent compound lycopene. Lastly, we are the first to report that the lycopene metabolite, apo-
12’-lycopenal, reduces proliferation of DU145 cells through modulation of cell cycle progression. 
Altogether, our results suggest that lycopenoids produced by cell metabolism or by oxidation 
may be bioactive and play a role in reducing prostate cancer risk. 
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Figure 3.1.  a: Effect of varying concentrations of lycopene on the 72 hour proliferation of 
DU145 cells. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. b: DU145 cells were 
treated with lycopene and analyzed by flow cytometry using Annexin V-FITC and Propoidium 
Iodide dyes c: Propidium Iodide was used for detection of cell cycle distribution by flow 
cytometry in DU145 cells after treatment with varying concentrations of lycopene for 72 hours. 
Data are presented as a percentage of the control cells treated with vehicle only plus placebo 
beadlets. Bars are means of three independent experiments ± SEM. Asterisk indicates 
significantly different from control cells. Lycopene significantly reduced DU145 cell 
proliferation (n=3), apoptosis (n=9), and accumulation of cells in the S phase (n=9) (ANOVA, 
p<0.05).  
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Figure 3.2. Gap junction protein, Connexin 43 (Cx43), levels in DU145 with: a. lycopene or b. 
apo-12’-lycopenal treatment. GAPDH was included as a control for loading. All panels denote a 
representative Western blot of three independent experiments. 
 
 
 
 
Figure 3.3.  Effect of replacing media and lycopene treatment daily (changed) or not changing 
media and lycopene treatment daily (unchanged) on the proliferation of DU145 cells. Cells were 
treated with 10μM lycopene for 72 hours. Cell numbers are expressed as the percentage of the 
control cells and bars are means of three independent experiments ± SEM. Asterisk indicates 
significantly different from control cells. Unchanged media and lycopene treatment significantly 
reduced proliferation of DU145 cells (ANOVA, p<0.05, n=3). 
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Figure 3.4. a: Effect of varying concentrations of apo-12’-lycopenal on the 72 hour proliferation 
of DU145 cells. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. b: DU145 cells were 
treated with apo-12’-lycopenal and analyzed by flow cytometry using Annexin V-FITC and 
Propidium Iodide dyes c: Propidium Iodide was used for detection of cell cycle distribution by 
flow cytometry in DU145 cells after treatment with varying concentrations of apo-12’-lycopenal 
for 72 hours. Data are presented as a percentage of the control cells treated with vehicle only. 
Bars are means of three independent experiments ± SEM. Asterisk indicates significantly 
different from control cells. Apo-12’-lycopenal significantly reduced proliferation of DU145 
cells, apoptosis, and accumulation of cells in the S phase (ANOVA, p<0.05, n=3). 
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CHAPTER IV 
TOMATO POWDER OR LYCOPENE REDUCES SERUM AND TESTES 
TESTOSTERONE AND ENZYMES CONTROLLING ANDROGEN AND ESTROGEN 
METABOLISM IN MICE LACKING CAROTENE MONOOXYGENASE I 
ABSTRACT  
 Serum levels of lycopene, the red pigment of tomatoes, are inversely associated with 
prostate cancer incidence while serum sex steroids, testosterone, dihydrotestosterone, and 
possibly estrogen, are associated with increased risk. Previously, we reported that serum 
testosterone was reduced in rats fed lycopene-containing diets. In this study, transgenic mice 
lacking the expression of carotene-monooxygenase II (CMO-II KO), wild-type mice, or mice 
with increased expression of CMO-II in the testes (CMO-I KO)  were used to investigate the 
effects of lycopene metabolism on sex steroid status. The lycopene (p=0.015) and tomato powder 
diets (p=0.0062) significantly reduced testicular testosterone in CMO-I KO mice after 4-d of 
feeding. Serum testosterone was also reduced in CMO-I KO mice by 4-d of consuming the 
lycopene (p=0.012) and the tomato powder (p=0.017) diets. The genes for the sex steroid 
metabolizing enzymes, 5α-reductase, and 17β-hydroxysteroid dehydrogenase, were also altered 
in response to dietary lycopene in the testes of CMO-I KO mice (p=0.001). The mRNA 
expression of the testicular androgen (p=0.0008) and estrogen (p<0.0001) receptors was down-
regulated by dietary lycopene in CMO-I KO mice. We hypothesize that lycopene metabolites, 
produced through oxidative cleavage by CMO-II, reduced serum testosterone alone, or in 
combination with the parent compound, lycopene. A small reduction in androgen and estrogen 
status by tomato powder and lycopene following short term feeding may reduce the risk of 
prostate cancer over a lifetime. 
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INTRODUCTION  
 Prostate cancer is the second most common cancer accounting for over 192,000 new 
cases in 2009 with approximately 27,000 deaths (1).  The cumulative cost of prostate cancer over 
five years is estimated to exceed $42,000 (2). Moreover, African-American men are more likely 
to develop prostate cancer and more likely to die from this disease. According to the 2004 US 
census, the average African-American household income was only $30,134. Therefore, the group 
of men with the greatest risk of developing prostate cancer cannot afford the current treatment 
options. Furthermore, current treatment options have unwanted side-effects with up to 43% of 
men experiencing sexual problems, 16% with urinary problems, and up to 11% of men 
experience bowel problems two years after treatment (3). For these reasons and because prostate 
cancer normally progresses slowly, dietary intervention is a plausible alternative to reduce 
prostate cancer risk. 
 The risk of prostate cancer is strongly associated with androgen status (4, 5). Additionally, 
a causal relationship is suggested in a few case reports of prostate cancer patients that previously 
used androgens for medical treatment or as anabolic agents (6, 7). Additionally, administration of 
testosterone is commonly used to induce prostate cancer in rodent models (8-11). Androgens can 
be converted to estrogens by the enzyme aromatase. Although androgen modulation has been the 
conventional method of prostate cancer treatment, it is apparent in recent literature that estrogens 
also play a role in prostate cancer development and treatment (12-18).  
 In a pivotal study published in 1995 using the Health Professional Follow-up Study 
cohort, intake of tomato products and their red pigment, lycopene, was associated with a 
decreased risk of prostate cancer (19). Notably, consuming three to five servings of tomato 
products a week reduced the risk of prostate cancer (19).  Dietary intervention studies have 
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recently evaluated a possible
 
diet-endocrine interaction in prostate cancer prevention (20-23).  In 
a phase II randomized-controlled trial, serum free testosterone was decreased with lycopene 
supplementation in men with clinically localized prostate cancer (24). Previously we reported 
that serum testosterone concentrations were significantly decreased in rats fed lycopene or 
tomato powder for 4-d (25) although longer term lycopene feeding did not alter serum 
testosterone or DHT levels (26).  Furthermore, we reported that lycopene accumulation was 
enhanced in castrated rats (27, 28).  Other studies reported reduced mRNA expression of the 
androgen metabolizing gene 5α-reductase in the prostate and in prostate tumors when rats were 
fed lycopene for four or eight wk (20, 21).   
 To our knowledge, no studies have investigated the effects of lycopene on estrogens in 
testes or prostate. However, a couple of studies have investigated the effects of lycopene on 
estrogen status in other tissues. Within the Women’s Health Initiative Observational Study, 
women had a reduced risk of developing estrogen receptor-positive and progesterone receptor-
positive breast cancers with higher intakes of lycopene or β-carotene (29). This inverse 
association was not found with other types of breast cancer suggesting that lycopene and β-
carotene may alter breast cancer risk through the estrogen and progesterone receptors. An in 
vitro study found that the carotenoids lycopene, phytoene, phytofluene and β-carotene, inhibited 
estrogen signaling and reduced proliferation of hormone-dependent MCF-7 and T47D breast 
cancer and ECC-1 endometrial cancer cells (30). Together, these data suggest that lycopene 
alters estrogen status within the endometrial and breast tissues. 
 Lycopene is the predominant carotenoid in tomato products. Tomatoes also contain other 
carotenoids, including β-carotene which is metabolized by carotene monooxygenase I (CMO-I) 
through central chain cleavage to form vitamin A and further metabolism results in formation of 
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retinoic acid and other retinoids (31). Carotene monooxygenase II (CMO-II) is responsible for 
eccentric cleavage of carotenoids, including lycopene to form aldehyde metabolites (Chapter 2 
(32)).  
 Recently, studies have identified and characterized lycopene metabolites and oxidative 
products generated in vivo. Some of these compounds demonstrate anti-cancer activity by 
inhibiting proliferation, inducing apoptosis, or enhancing cell to cell communication (33-35).  
Interestingly, in vivo concentrations of lycopene metabolites, also known as lycopenoids (36), 
are of comparable biological concentrations to retinoids produced from β-carotene.  Like 
retinoids, we propose that carotenoid metabolites, produced through eccentric cleavage by CMO-
II, are bioactive in small concentrations within tissues (36). Additionally, we hypothesize that 
lycopenoids, in combination with lycopene or other tomato components, reduce prostate cancer 
risk.      
 We and others have reported that lycopene alters androgen and estrogen status in rats, 
cell-culture, and clinical studies (20-25). The current study investigates the effects of lycopene-
containing diets on testosterone and estrogen status and further investigates possible mechanisms. 
Specifically, we investigated how the metabolism of lycopene affects sex steroid status using 
transgenic mice that lack the production of oxidative lycopene metabolites (CMO-II KO), wild-
type mice, or mice with increased expression of CMO-II in the testes (CMO-I KO).  Whether 
through intact lycopene or its metabolites, consuming lycopene or tomato products may provide 
a cost-effective way to manage prostate cancer risk over a man’s lifetime through a moderate 
reduction in testosterone and estrogen.  
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MATERIALS AND METHODS 
Mouse husbandry and diets.  
 We received breeder pairs of Bcmo1tm1Dnp (CMO-I KO, n=4) and B6;129S6-
Bcdo2tm1Dnp (CMO-II KO, n=4) courtesy of collaborators, Drs. Adrian Wyss at DSM 
Nutritional Products (Basel, Switzerland) and Johannes von Lintig at Case Western Reserve 
University. The generation of CMO-I KO mice was previously described (37). The generation of 
CMO-II KO mice is described by (Amenguel, submitted). C57BL/6  x 129/SvJ (F1) mice (WT, 
n=40) were purchased from Jackson Laboratory (Bar Harbor, ME). For this study, CMO-I KO 
and CMO-II KO mice were bred at the University of Illinois animal facilities. Genomic DNA 
from mouse tail biopsies and the Sigma Extract-N-Amp Tissue PCR Kit (St. Louis, MO) were 
used to confirm the genotype of the mice. Mice were housed in shoebox cages with free access to 
water and weighed and handled daily. Six to nine wk old male mice consumed an AIN-93G diet 
for 3 wk prior to randomization onto experimental diets. Fresh diet was provided every 48 hr and 
new diet was made monthly. The diet was stored in the dark at 4ºC.   
 Nine- to 12-wk old male mice were randomly assigned to one of two experimental 
lycopene-containing diets; 10% tomato powder (Futureceuticals) (TP), or lycopene (DSM, 10% 
water-soluble lycopene beadlet) (LYC). The TP group was compared to an AIN-93G dietary 
group while the LYC group was compared to a placebo beadlet (PB) dietary group; n=25 per 
genotype/diet. Because previously we demonstrated that 4-d of feeding or orally gavaging 
lycopene, tomato powder, and phytofluene significantly reduced serum testosterone in rats, the 
mice in this study also consumed the experimental diets for 4-d, ad libitum. At the conclusion of 
the study, mice were asphyxiated by CO2 and blood was collected by cardiac puncture. Cohorts 
of mice were sacrificed daily in the afternoon within a three hr time frame to avoid diurnal 
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alterations in serum testosterone. Brain, thymus, lungs, liver, spleen, duodenum mucosa, kidneys, 
adrenals, seminal vesicles, testes, and prostate were removed and snap-frozen in liquid nitrogen 
and then stored at -80ºC. All animal procedures were approved by the University of Illinois 
Institutional Animal Care and Use Committee. 
 The TP diet contained 204 nmol lycopene/g diet while the LYC diet provided 248 nmol 
lycopene/g diet. The TP diet also contained additional carotenoids: 10.1 nmol phytoene, 2.6 
nmol phytofluene, 1.3 nmol β-cryptoxanthin, and 0.8 nmol β-carotene/g diet. All diets were 
balanced for total fiber, nitrogen, and calories (Chapter 2). Additionally, vitamin A levels were 
reduced in all diets to 1500 IU retinyl palmitate per kg diet to ensure adequate absorption of 
carotenoids without resulting in a vitamin A deficiency (38). 
HPLC analysis of carotenoids.  
 All chemicals were purchased from Fisher Scientific (Pittsburgh, PA). Tissue and serum 
samples were extracted with hexanes as described previously with minor modifications (Chapter 
2) (27). Briefly, 0.08g tissue (0.15g liver was used for β-carotene analysis in study 1) was added 
to 5 ml of ethanol containing 0.01% butylated hydroxytoluene (BHT). Saturated KOH was added 
and the samples were vortexed. The samples were saponified in a waterbath at 60ºC for 30 
minutes with vortexing every 10 minutes. Distilled water (2 ml) was added and carotenoids were 
extracted three times with hexanes (6 ml). Serum carotenoids were extracted from 0.15 ml serum 
in 0.15 ml ethanol/BHT solution with 0.15 ml distilled water and 1.5 ml hexanes.  
 All extracts were kept on ice under yellow lights and flushed with argon to prevent 
degradation. For analysis, samples were dissolved in methyl-tert-butyl ether and injected onto a 
C30 HPLC column (4.6 x 150 mm, 3µm; YMC, Wilmington, NC) maintained at 18ºC. A 
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reverse-phase HPLC-PDA method was utilized (39, 40). Individual carotenoids were identified 
by comparison of elution times to standards and absorption spectral analysis.  
Serum and testes testosterone.  
 Testicular testosterone was extracted as previously described with minor modifications 
(41). Briefly, half of a testis was homogenized in PBS (125 µl) at room temperature for 20 s. 
Diethyl ether (2.5 ml) was added, the sample was vortexed for 2 min, and then centrifuged at 183 
x g for 1 min. The upper phase was removed and saved. Another 1.4 ml diethyl ether was added, 
the sample was vortexed and placed on dry ice for 10 min. The upper phase was again removed 
and combined with the previous extract. Samples were allowed to evaporate at room temperature 
and stored at -80°C until use. Samples were diluted 1:10 in PBS before quantification by 
radioimmunoassay. Serum and testicular testosterone were quantified with a radioimmunoassay
 
kit (DSL-4000 ACTIVE Testosterone Coated-Tube
 
Radioimmunoassay Kits; Diagnostic 
Systems Laboratories) as per manufacturer’s instructions. 
Real-Time PCR analysis.  
 Relative tissue expression of genes were evaluated using a Trizol (Invitrogen, Carlsbad, 
CA) extraction as per manufacturer’s instructions followed by Dnase I treatment with the 
following modifications (New England Biolab, Ipswich, MA) (Table 4.1). Prostate tissue mRNA 
was extracted with 2 ml Trizol and testicular tissue mRNA was extracted using 1.5 ml Trizol. 
Concentration and quantity of mRNA were determined by spectrophotometry and agarose gel 
electrophoresis before synthesis of complimentary DNA by Superscript II Reverse Transcriptase 
(Invitrogen) using
 
random hexamers (Applied Biosystems, Foster City, CA). CMO-I and CMO-
II primers have been published previously (Chapter 2) while all other primers are listed in Table 
1. Real-time PCR was performed using a 7900HT Fast Real-Time PCR detection system 
 98 
 
(Applied
 
Biosystems) with the SYBR green fluorescence dye. Threshold cycle (Ct) values for the 
18S, β-actin, and L7a gene were used as control genes. 
Statistical analysis.  
 A 3 x 4 factorial design was used with three genotypes (CMO-I KO, wild-type, or CMO-
II KO) and four diets (AIN, TP, LYC, or PB). Interactions between genotype and diet were 
investigated. All parameters were analyzed by analysis of variance (ANOVA) followed by 
Tukey’s post hoc analysis using SAS 9.2 (Cary, NC) with α = 0.05. When assumptions for 
ANOVA were violated, data were transformed by natural log. For analysis of serum and 
testicular testosterone, all data points outside two standard deviations were considered extreme 
outliers and were removed from the dataset. Results were expressed as means ± SEM, unless 
otherwise specified.  
RESULTS 
Tomato powder and lycopene reduced serum and testes testosterone.  
 Consumption of the LYC and the TP diet significantly reduced serum and testicular 
testosterone concentrations in CMO-I KO mice (Figure 4.1). Testosterone was also significantly 
reduced in the testiss of CMO-II KO mice consuming the TP diet. The experimental diets did not 
alter serum or testes testosterone in wild-type mice or serum testosterone in CMO-II KO mice. 
Lycopene-containing diets altered testicular mRNA expression of sex steroid metabolizing 
genes and receptors. 
 The mRNA expression of the androgen receptor, estrogen receptor α, estrogen receptor β, 
steroid hormone binding globulin, aromatase, 5α-reductase I, 5α-reductase II, 17β-hyroxysteroid 
dehydrogenase I, and 17β-hydroxysteroid dehydrogenase IV were measured in the testis. The 
LYC and TP diets affected the expression of steroid metabolizing genes in CMO-I KO mice 
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(Table 4.2). The lycopene diet significantly decreased the mRNA expression of the androgen 
receptor and 5α-reductase I in the testes of CMO-I KO mice (p=0.01). Consumption of the TP 
diet significantly up-regulated mRNA expression of 17β-hydroxysteroid dehydrogenase I (17β-
HSD I) (p=0.01) and 17β-hydroxysteroid dehydrogenase IV (17β-HSD IV) (p=0.0004) in the 
testes of CMO-I KO mice. The expression of the estrogen receptor alpha was significantly 
decreased in CMO-I KO mice compared to CMO-II KO and wild-type mice consuming the 
lycopene diet (p<0.0001). The expression of steroid metabolizing genes was also altered in 
CMO-II KO mice consuming the lycopene-containing diets. The mRNA expression of the 
androgen receptor in the testis was significantly increased in CMO-II KO mice that consumed 
the lycopene diet (p=0.008) and but not by the TP diet (Table 4.2). Consumption of the lycopene 
diet also resulted in a slight decrease in the expression of 5α-reductase I. The expression of 
estrogen receptor alpha was significantly up-regulated in CMO-II KO and wild-type mice that 
consumed the lycopene diet. The experimental diets did not affect the mRNA expression of other 
genes investigated. 
CMO-I KO mice and CMO-II KO mice have altered mRNA expression of steroid 
metabolizing genes.  
 The mRNA expression of steroid metabolizing genes was altered in testis and prostate of 
CMO-I KO and CMO-II KO mice compared to wild-type mice (Figure 4.2 and Table 4.4). The 
mRNA expression of 5α-reductase I was reduced in the testes of CMO-I KO and CMO-II KO 
mice while the mRNA expression of 5α-reductase II was also reduced in the testes of CMO-II 
KO. The mRNA expression of testicular aromatase and estrogen receptor beta and prostatic 
androgen receptor was elevated in CMO-II KO mice. The mRNA expression of the 17β-HSD 
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isoforms 1 and 4 were upregulated in the testes and prostate of CMO-I KO mice and testes of 
CMO-II KO mice. 
Dietary lycopene and tomato powder altered the expression of hepatic PPAR-γ but not 
CYP26a1.  
 The TP and LYC diets increased the hepatic mRNA expression of PPAR-γ in CMO-I KO 
mice (Figure 4.3). The LYC diet increased expression of hepatic PPAR-γ and the TP diet 
reduced expression of PPAR-γ in wild-type mice. The dietary interventions in this study did not 
affect hepatic CYP26a1 mRNA expression (Table 4.3). On the other hand, overall, CMO-II KO 
mice had reduced mRNA expression of hepatic CYP26a1 (p<0.0001). 
Short term feeding of lycopene or tomato powder results in preferential accumulation of 
carotenoids in CMO-I KO mice and CMO-II KO mice and alterations in CMO gene 
expression.  
 CMO-II KO mice preferentially accumulated tissue and serum lycopene after 4 d of 
consuming a LYC or TP diet (p<0.0001) (data not shown). CMO-I KO mice accumulated 
significantly less hepatic lycopene compared to WT mice (p<0.0001). CMO-I KO mice 
preferentially accumulated tissue and serum β-carotene compared to wild-type and CMO-II KO 
mice (p<0.0001). The mRNA expression of CMO-I and CMO-II was investigated in the liver, 
duodenum, prostate, and testes of mice. The mRNA expression of CMO-II was significantly 
down-regulated in the prostate (p<0.0001) and up-regulated in the testes (p=0.004) of CMO-I 
KO mice compared to wild-type mice. The mRNA expression of CMO-I was not altered in 
CMO-II KO mice. The lycopene-containing diets did not affect CMO-I or CMO-II mRNA 
expression (data not shown). 
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DISCUSSION 
 Normal growth and function of the prostate requires sex steroids although higher serum 
levels of androgens, testosterone and dihydrotestosterone (DHT), and higher estrogens are 
reported to be associated
 
with increased prostate cancer risk (5, 12, 13, 16, 42-44).  Previously, 
we reported that serum testosterone was reduced in rats that consumed lycopene or tomato 
powder for 4-d (25). In contrast, longer term feeding of lycopene-containing diets (22 wk) did 
not alter serum testosterone (26, 45).Here, we show in a second animal model that consumption 
of lycopene and tomato powder has modest effects on testosterone levels and metabolism of sex 
steroids which may translate to a reduced risk of prostate cancer over a man’s lifetime. Because 
these effects were primarily found in CMO-I KO mice, the current study further suggests that 
metabolites of lycopene reduce serum and testes testosterone in mice (Figure 4.1).  
 The testis is the primary site of testosterone production in the human and rodent. 
Therefore, we investigated the effects of tomato powder and lycopene on testosterone production 
the testes and in circulation. The TP and LYC diets significantly reduced serum and testes 
testosterone in CMO-I KO mice by 30-40% (Figure 4.1). Additionally, the mRNA expression of 
5α-reductase I was significantly reduced in the testes of CMO-I KO mice that consumed the 
lycopene diet.  Testosterone is converted to the more active androgen, DHT, by 5α-reductase. 
The enzyme, 5α-reductase I, is predominantly expressed in the testes (Table 4.2) while isoform II 
is more highly expressed in the prostate. Current androgen ablation therapies, Dutasteride and 
Finasteride, target 5α-reductase to reduce serum DHT levels by 65-98% (13, 46). In contrast, 
serum testosterone levels significantly increase with these treatments (47-49). Although DHT has 
a much higher binding affinity for the androgen receptor, testosterone is also a ligand for the 
androgen receptor and may induce transcription of target genes. The lycopene-containing diets 
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used in this study significantly reduced serum testosterone and possibly DHT synthesis through 
reduced expression of 5α-reductase in the testes. Therefore, lycopene appears to moderately 
reduce both serum androgens which may result in a reduced risk of prostate cancer. 
 Not only is the ligand testosterone (and possibly DHT) reduced in CMO-I KO mice, but 
the expression of the androgen receptor is also reduced in the testes by lycopene-containing diets. 
CMO-II KO mice have the highest mRNA expression of the androgen receptor, followed by 
wild-type, and CMO-I KO mice (Table 4.2). These data would suggest reduced transcription of 
androgen-related genes in the testes of CMO-I KO mice by lycopene-containing diets. 
 The role of estrogens in prostate cancer treatment and development is not clear at this 
time. Estrogen can inhibit synthesis of testosterone and has more traditionally been used as a 
prostate cancer therapeutic (12, 13, 15). In contrast, other studies have reported that estradiol is 
integral for prostate cancer development (13, 14, 16, 18). In this study, the lycopene-containing 
tomato powder diet up-regulated the expression of 17β-hydroxysteroid dehydrogenase (17β-
HSD). It is important to note that the androgen pathways in the rodent and human differ. The 
rodent 17α-hydroxylase enzyme is more active on 4-ene steroids while the human enzyme 
specificity prefers 5-ene steroids (50-52). As a result, rodents do not produce 
dehydroepiandrosterone (DHEA) but instead 4-androstenedione. Therefore, the 17β-HSD 
enzyme isoforms I and IV are primarily responsible for activation and inactivation of estradiol, 
respectively. Consumption of the TP diet significantly increased the expression of 17β-HSD I 
and IV in CMO-I KO mice (Table 4.2). Isoform I is responsible for conversion of estrone to the 
more potent steroid, estradiol, whereas, isoform IV inactivates estradiol to estrone. The type IV 
isoform is much more highly expressed (>80x) in testis. Therefore, we hypothesize that up-
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regulation of both isoforms of 17β-HSD would result in a net inactivation of estradiol to estrone 
by lycopenoids in CMO-I KO mice.  
 The lycopene diet also down-regulated the expression of estrogen receptor (ER) alpha in 
the testes of CMO-I KO mice compared to wild-type and CMO-II KO mice. The primary 
isoform found in the prostate is ERβ, although expression is lost with development of prostate 
cancer which parallels induced expression of ERα in prostate cancer cells (43). The binding of 
estrogens to ERα induces proliferation, inflammation, and development of premalignant lesions 
while ERβ reduces proliferation and in general acts as a tumor suppressor (44). Therefore, it has 
been hypothesized that tissue expression levels of estrogen receptors radically affects growth, 
differentiation, malignancy and treatment of prostate cancer. The lycopene-containing diets may 
reduce prostate cancer risk by inducing 17β-HSD IV and reducing estrogen receptor alpha 
expression in CMO-I KO mice. 
 Overall, the lycopene-containing diets (LYC and TP) reduced serum and testes 
testosterone, expression of testicular androgen receptor, testicular estrogen receptor, and altered 
other sex steroid metabolizing genes in CMO-I KO mice. CMO-I KO mice have significantly 
induced expression of the eccentric carotenoid cleavage enzyme, CMO-II, in the testes and 
reduced tissue lycopene accumulation compared to wild-type mice (Chapter 2). Therefore, we 
hypothesize that testosterone is significantly reduced in CMO-I KO mice due to increased 
production of lycopenoids.  
 Evidence suggests the positive effects of the lycopene-containing diets on sex steroid 
status is due to lycopenoids rather than decreased production of retinal by CMO-I cleavage. 
Although CMO-I KO mice have a substantially reduced ability to convert pro-vitamin A 
carotenoids to retinal, vitamin A deficiency has not been noted in these mice (37, 38).  The diet 
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provided a reduced level of retinyl palmitate relative to NRC requirements for rodents, but this 
level is adequate enough to avoid vitamin A deficiency symptoms in the current and previous 
longer term feeding studies (37, 38).  Interestingly, we have determined that wild-type mice lack 
the mRNA expression of CMO-I in the prostate (Chapter 2). This might suggest that retinoids do 
not have a functional role in the prostate of adult male mice. Therefore, lycopenoids, but not 
retinoids, may have reduced serum and testes testosterone levels in mice consuming LYC or TP 
diets.  
 Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists have been shown 
to inhibit the production of estradiol and testosterone, decrease prostate tumor growth, and 
decrease a signaling target of DHT, prostate specific androgen (PSA) (53-56). We previously 
showed that lycopene diets decrease the expression of PPAR- γ in the kidney and adrenal of rats 
(57). In contrast, we also reported that a lycopene-containing diet increased the expression of 
PPAR-γ in the prostate of castrated rats (25). In the current study, lycopene may have reduced 
testosterone production by targeting PPAR-γ. The mRNA expression of hepatic PPAR-γ in 
CMO-I KO mice was significantly up-regulated when mice consumed the LYC or TP diets 
(Figure 4.3). This study suggests that activation of PPAR-γ by lycopene or its metabolites may 
inhibit testosterone synthesis.  
 Surprisingly, some alterations in sex steroid status were also found in CMO-II KO mice. 
The lycopene-containing diets increased the mRNA expression of 17β-HSD IV and estrogen 
receptor alpha in the testes of CMO-II KO mice (Table 4.2). These data may suggest that 
estradiol synthesis is down-regulated and negative feedback is causing increased expression of 
the estrogen receptor in the testes of CMO-II KO mice. Testosterone levels in the testis were also 
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decreased in CMO-II KO mice consuming the lycopene diet. These data suggest that intact 
lycopene may have some moderate effects on estrogen and testosterone concentrations or activity. 
  The basal expression of steroid metabolizing genes was altered in the transgenic mice 
and may predict prostate cancer susceptibility in these models. Overall, significant changes in the 
mRNA expression of 5α-reductase I and 17β-HSD IV were identified in the testes and alterations 
in expression were found in both isoforms of 17β-HSD within the prostate of CMO-I KO mice 
(Figure 4.2 and Table 4.4). CMO-II KO mice had significant alterations in the mRNA expression 
of 5α-reductase I and II and aromatase in the testis, and alterations in the expression of the 
androgen receptor in the prostate of CMO-II KO mice.  
 Consuming lycopene-containing foods may prove a cost-effective, dietary approach to 
reduce prostate cancer risk with few side effects. In this short term, 4-d feeding study, the 
lycopene-containing diets reduced serum and testes testosterone and decreased expression of 5α-
reductase I and the androgen receptor in the testes of CMO-I KO mice. The lycopene-containing 
diets also reduced expression of 17β-HSD IV and the estrogen receptor in the testes of CMO-I 
KO mice.  Our previous work with rats demonstrates that 4-d of feeding lycopene or tomato 
powder reduces serum testosterone (25) but this effect was not seen with chronic feeding for 
months (26, 45). This may suggest that intermittent consumption of tomato powder or lycopene 
may have anti-androgenic effects in the testes which matches human feeding patterns whereby 
man may eat 3-5 servings of tomatoes a week to reduce prostate cancer risk.. Clearly, more work 
needs to be done to follow-up on this speculation. 
 Evidence suggests CMO-I KO mice may produce more bioactive lycopene metabolites in 
the testes compared to wild-type mice, therefore, we hypothesize that the positive effects of the 
lycopene-containing diets found in this study can be attributed at least in part to lycopenoids. 
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This is the first report of the effects of dietary lycopene on estrogen status in the mouse testes 
and prostate. Furthermore, these data suggest that consuming tomato products or lycopene a few 
days a week over a lifetime may reduce prostate cancer risk by moderately reducing androgens 
and estrogens.  
 
Table 4.1. Primers used for Real-Time PCR analysis. 
Gene Accession number Forward/reverse primers 
Androgen receptor NM_013476.3 5’-GGCCCCCATCCAAGACCTATC-3’ 
  5’-CAGCTGCCTCCCCGAGCC-3’ 
SHBG NM_011367.2 5’-ACATTGACCCTGCCCTGAGAC-3’ 
  5’-CGCTCGTGCCTGCCCTG-3’ 
Aromatase NM_007810.2 5’-CCC GGA AAC TGT GAC TGT CA -3’ 
  5’-GAG AAG GAG GCC CAT GAT CA -3’ 
5α-reductase I NM_175283.3 5’-CTGGAGGGTTTCCTGGCTTTC-3’ 
  5’-AAGCCCACCCTGCTGTTCAC-3’ 
5α-reductase II NM_053188.2 5’-GTGCCATCAGGTCCCGGT-3’ 
  5’-GCTGGGTCTCTTCTCCGCACA-3’ 
17β-HSD I NM_010475.1 5’-GCT CCT CTG GAA TCG GCA TGC-3’ 
  5’-CCA CAC GAC CCT CAG TCA CG-3’ 
17β-HSD IV NM_008292.2 5’-CCA TCG TCA GAA AGC GGA AT-3’ 
  5’-CTT CTC CCA GTT GTC CCT CAC T -3’ 
Cyp26a1 NM_007811.1 5’- CAG TGC TGC GAC ATC ACT GA-3’ 
  5’-CGA ACT TTC TGG AGG ACA TGT G-3’ 
PPAR-γ NM_011146.2 5’-GCC CAC CAA CTT CGG AAT C-3’ 
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Table 4.1 (cont.)   
Gene Accession number Forward/reverse primers 
  5’-TGC GAG TGG TCT TCC ATC AC-3’ 
18S NR_003278.1 5’-GAT CCA TTG GAG GGC AAG TCT-3’ 
  5’-AAC TGC AGC AAC TTT AAT ATA CGC-3’ 
β-actin NM_007393.2 5’-CGT GAA AAG ATG ACC CAG ATC A-3’ 
  5’-AGC CTG GAT GGC TAC GTA CAT G-3’ 
L7a NM_013721.3 5’-CCT CTA CAA GCG GCT CAA AGT C-3’ 
  5’-CCA GGG CCT GGG TGA AC-3’ 
ERα NM_01193.4 5’-GGA GTA CTG CCT GCT GAA AGC T-3’ 
  5’-CAC AGC CTC AGC ATC TTC AAT G-3’ 
ERβ NM_007953.2 5’-CTC AGC CAG CCG GAA CTC-3’ 
  5’-CAA AAA GAG CAG TGG GTA CAG AAC-3’ 
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Table 4.2. Testicular steroid metabolizing gene expression in mice fed lycopene-containing diets. 
  Dietary intervention  
Gene PB LYC AIN  TP  
Androgen Receptor
1 
      
         Wild-type 37.1 ± 5.31
b 
36.9 ± 7.66
b 
39.5 ± 8.38
b 
 29.5 ± 8.32
ab  
         CMO-I KO 34.9 ± 6.23
b 
22.7 ± 1.94
a 
49.1 ± 11.1
bc 
 39.3 ± 9.32
b  
         CMO-II KO 42.1 ± 7.23
bc 
56.4 ± 7.03
c 
38.8 ± 7.40
b 
 46.4 ± 11.0
bc  
5α-reductase I2       
         Wild-type 79.2 ± 7.74
c 
83.1 ± 6.49
cd
  70.9 ± 7.83
bc 
 76.4 ± 6.26
bc  
         CMO-I KO 61.3 ± 2.86
b 
49.7 ± 7.14
a 
56.6 ± 7.28
ab 
 59.5 ± 11.1
ab  
         CMO-II KO 96.6 ± 9.43
d 
85.3 ± 6.38
cd 
102 ± 10.09
d 
 82.2 ± 7.80
cd  
17β-HSD I3       
         Wild-type 1.19 ± 0.15
bc 
1.25 ± 0.17
bc 
1.47 ± 0.21
c 
 1.26 ± 0.29
bc  
         CMO-I KO 0.71 ± 0.12
b 
0.67 ± 0.39
b 
0.25 ± 0.04
a 
 1.20 ± 0.33
bc  
         CMO-II KO 1.10 ± 0.26
bc 
2.05 ± 0.59
c 
1.13 ± 0.20
bc 
 2.23 ± 0.76
c  
17β-HSD IV3       
         Wild-type 58.1 ± 6.06
d 
66.6 ± 12.14
de 
68.1 ± 12.97
de 
 64.6 ± 10.52
d
 
 
         CMO-I KO 34.6 ± 5.83
bc 
24.5 ± 4.67
b 
16.1 ± 2.09
a 
 40.4 ± 4.30
c  
         CMO-II KO 60.4 ± 12.0
d 
93.5 ± 16.40
e 
86.4 ± 9.08
e 
 153 ± 44.4
e  
ER-α1       
         Wild-type 244 ± 63.6
b 
445 ± 130
c 
187 ± 70.0
ab 
 385 ± 84.3
c  
         CMO-I KO 253 ± 84.8
b 
137 ± 9.77
a 
366 ± 95.4
b 
 224 ± 78.8
ab  
         CMO-II KO 232 ± 63.2
b 
461 ± 97.1
c 
226 ± 66.4
b 
 380 ± 83.0
c  
 
 109 
 
Table 4.2 (cont.)  
1
Compared to L7a. 
2
Compared to beta-actin. 
3
Compared to 18s. 
Letters signify significantly different; p<0.05. Means ±SEM. n=9-11. 
 
 
Table 4.3. Hepatic cyp26a1 mRNA expression is altered in CMO-II KO mice, but not affected 
by dietary lycopene or tomato powder.  
Diet Wild-type CMO-I KO CMO-II KO 
PB 1.16 ± 0.24
a 
0.95 ± 0.35
 a
 0.24 ±0.08
 b
 
LYC 1.15 ± 0.33
 a
 0.92 ± 0.46
 a
 0.36  ±0.11
 b
 
AIN 1.13 ± 0.33
 a
 0.34 ± 0.17
 ab
 0.37 ± 0.09
 b
 
TP 0.63 ± 0.13
 a
 0.46 ± 0.14
 ab
 0.31  ± 0.06
 b
 
Letters signify significantly different; p<0.05. Means ±SEM. n=9-11. 
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Figure 4.1. CMO-I KO mice, CMO-II KO mice, and wild-type mice were fed AIN-93G diet 
(AIN) or diets supplemented with tomato powder (TP), lycopene water-soluble beadlets (LYC), 
or placebo beadlets (PB) for 4-d and then serum and testes testosterone were measured. Serum 
(A) and testes (B) testosterone were quantified with a radioimmunoassay
 
kit (DSL-4000 
ACTIVE Testosterone Coated-Tube
 
Radioimmunoassay Kits; Diagnostic Systems Laboratories). 
Bars represent means ± SEM. For each variable, labeled means without a common letter differ, 
p<0.05; serum n=10-15, testes n=8-10. 
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Figure 4.2. Steroid metabolizing genes were altered in the testis and prostate of CMO-I KO mice 
(A), and testis and prostate of CMO-II KO mice (B). mRNA expression was quantified by Real 
Time PCR and are expressed as 2
-ΔΔCt
*1000. The mRNA expression of aromatase, androgen 
receptor (AR), and estrogen receptor (ERβ) were compared to L7a, 5α reductase I and 5α 
reductase II were compared to β-actin, and 17β-hydroxysteroid dehydrogenase I (17β-HSD I) 
and 17β-hydroxysteroid dehydrogenase IV (17β-HSD IV) were compared to 18S ct values. 
Additional isomers of 17β-HSD acting on these substrates include: 1isomers 3,5; 2isomers 2,10; 
3
isomers 3,5,15; 
4
isomers 2,9,10; 
5
isomers 1,12; 
6
isomers 2,8,14. Adapted from Luu-The, et al 
(58). 4-dione, 4-androstenedione; A-dione, androstenedione; T, testosterone; DHT, 
dihydrotestosterone; E2, estradiol; E1, estrone. Significant increases in mRNA expression are 
noted with bolded line or text and reductions in mRNA expression are noted with dashed line 
and reduced text size. 
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Testis Prostate 
        Gene  Genotype  P-value  Gene  Genotype  P-value  
5α-reductase I  ↓ CMO-I KO  <0.0001  17β-HSD I  ↑ CMO-I KO  <0.0001  
5α-reductase I  ↓ CMO-II KO  <0.0001  17β-HSD IV  ↑ CMO-I KO  <0.0001  
5α-reductase II  ↓ CMO-II KO   0.0085  AR  ↑ CMO-II KO  <0.0001  
Aromatase  ↑ CMO-II KO   0.0071     
17β-HSD IV  ↓ CMO-I KO  0.0231     
17β-HSD IV  ↓ CMO-II KO  <0.0001     
ER β  ↑ CMO-II KO  0.0232     
Table 4.4. The p-value for genes with significant alterations in basal mRNA expression for each 
genotype, n=9-11. 
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Figure 4.3. Hepatic PPAR-γ mRNA expression is upregulated in CMO-I KO mice. Results are 
expressed as 2
-ΔCt
*1000 with β-actin as the control gene. Bars represent means ± SEM. For each 
variable, labeled means without a common letter differ, p<0.05; n=9-11. 
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CHAPTER V 
DISCUSSION AND FUTURE DIRECTIONS 
INTRODUCTION 
Lycopene is the predominant carotenoid in tomato products followed by phytoene, 
phytofluene, and β-carotene.  Beta-carotene is metabolized by carotene monooxygenase I (CMO-
I) through central chain cleavage to form vitamin A and further metabolism results in formation 
of retinoic acid and other retinoids. Metabolism of β-carotene is widely studied, but very little is 
known about the metabolism of other carotenoids. In vitro evidence suggests that lycopene is 
metabolized by carotenoid monooxygenase II (CMO-II). Enzymatic cleavage by CMO-II results 
in eccentric chain cleavage of carotenoids. Like retinoids, we propose that carotenoid metabolites 
produced through eccentric cleavage by CMO-II are bioactive in small concentrations within 
tissues. Additionally, we hypothesize that the metabolic products of lycopene and possibly other 
tomato carotenoids, alone and in combination with the parent compounds, reduce prostate cancer 
risk. In vivo studies identified and characterized tomato carotenoid metabolites and oxidative 
products. Levels of lycopene metabolites identified in vivo are of comparable biological 
concentrations to retinoids. Recent data suggests that lycopene metabolites are biologically 
active and affect important molecular targets and pathways. However, at this stage, the metabolic 
production of non-provitamin A carotenoids is poorly understood. Since we are one of only three 
labs breeding CMO-I KO and CMO-II KO mice, we have the unique opportunity to investigate 
the metabolism of non-provitamin A carotenoids in these models. Therefore, the overall 
objective of this thesis is to investigate the metabolism of carotenoids from tomatoes, in vivo, 
and its impact upon prostate cancer risk factors. 
Summary of study 1 
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 In the first study, we investigated the metabolism of tomato carotenoids, lycopene, 
phytoene, phytofluene, and β-carotene in novel transgenic mice lacking the carotenoid cleavage 
enzymes CMO-I or CMO-II. Lycopene preferentially accumulated in tissues of CMO-II KO 
mice compared to wild-type mice thereby demonstrating that lycopene is metabolized by CMO-
II in vivo. Interestingly, although phytoene and phytofluene are structurally similar to lycopene, 
neither CMO-I KO nor CMO-II KO mice preferentially accumulated these carotenoids 
suggesting they are not substrates for either enzyme. The differential expression of CMO-I and 
CMO-II in tissues suggests functional roles of lycopenoids or retinoids in those tissues. Of 
further interest, the prostate lacks CMO-I expression which suggests that retinoids do not have a 
function in the adult male prostate. We were surprised to find that the lycopene-containing diets 
did not affect the expression of either CMO-I or CMO-II in the duodenum, liver, testes, or 
prostate. Lastly, we again confirmed through bioaccumulation and mRNA expression data that 
β-carotene is primarily metabolized by CMO-I. 
Summary of study 2 
 The second study investigated the effects of lycopene and two of its oxidative metabolites, 
apo-12’-lycopenal, and apo-8’-lycopenal on prostate cancer cells, in vitro. Androgen-
independent DU145 cells were treated with physiological and supraphysiological concentrations 
of lycopene and its metabolites. Lycopene and apo-12’-lycopenal, but not apo-8’-lycopenal 
reduced proliferation of the DU145 cells only at supraphysiological concentrations. Further 
investigation of the mechanism of reduced proliferation suggests that lycopene and apo-12’-
lycopenal inhibit normal cell cycle progression but do not alter gap junction communication of 
DU145 cells. This study demonstrated bioactivity of oxidative lycopene metabolites, in vitro. 
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Summary of study 3 
 A previous study in our lab showed that short term feeding of lycopene or tomato powder 
significantly reduced serum testosterone. In the third study, CMO-I KO, CMO-II KO, and wild-
type mice were fed lycopene-containing diets for 4-d to investigate whether these diets 
influenced androgen or estrogen metabolism in mice. Serum and testicular testosterone were 
significantly reduced in CMO-I KO mice. CMO-I KO mice that consumed the lycopene-
containing diets had decreased expression of 5α-reductase I and the androgen receptor in the 
testes. Additionally, the experimental diets up-regulated expression of 17β-hydroxysteroid 
dehydrogenase and decreased expression of the estrogen receptor in the testes of CMO-I KO 
mice. Because CMO-I KO mice have induced expression of CMO-II in the testes and reduced 
accumulation of lycopene, this would suggest that CMO-I KO mice have an increased 
production of lycopenoids in this tissue. Therefore, results from the 3
rd
 study suggest that the 
expression of CMO-II and the production of lycopene metabolites significantly impacts sex 
steroid status in mice. In conclusion, a small reduction in androgen and estrogen status by tomato 
powder and lycopene following short term feeding might reduce the risk of prostate cancer over 
a lifetime. 
FUTURE DIRECTIONS 
 Based upon the results of this dissertation, four follow-up studies are proposed: 
1. TRAMP x CMO-II KO prostate cancer study 
2. Identification of novel lycopene, phytoene, and phytofluene metabolites 
3. Alterations in the expression of CMO-I and CMO-II in  mice 
4. Phenotype characterization of new transgenic mouse models 
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 The first future study is actually supported by an NIH grant that is ongoing with 
collaborators at The Ohio State University. CMO-II KO mice are being crossed with a mouse 
model of prostate cancer, TRAMP, to investigate the effects of carotenoid metabolism on 
prostate cancer risk. The TRAMP x CMO-II KO and TRAMP x WT mice are being fed lycopene, 
tomato powder, or a control diet starting before sexual maturity or the induction of pre-cancerous 
changes in the prostate. We hypothesize that lycopene metabolites produced through CMO-II 
cleavage will be effective in reducing prostate cancer risk. Therefore, we hypothesize that wild-
type mice will have significantly reduced prostate cancer progression compared to CMO-II KO 
mice that will produce fewer lycopene metabolites. 
 The second study will strengthen our current studies by identifying and quantifying 
carotenoid metabolites, in vivo. The metabolism of lycopene by CMO-II produces apo-
lycopenals. These aldehydes are quite unstable and highly reactive therefore make identification 
and quantification very difficult. Additionally, because the metabolites are produced in small 
concentrations and mouse tissues are quite small, future studies will necessitate pooling of 
tissues to try to quantify metabolites. We will use an HPLC-MS tandem system to optimize use 
of tissue. Additionally, 
14
C labeled lycopene, phytoene, and phytofluene can be used to trace the 
metabolism of carotenoids and synthesis of new metabolites. 
 The third proposed study investigates the effects of castration, age, sex, and progression 
of prostate cancer on the tissue expression of CMO-I and CMO-II in our mouse models. 
Previously, TRAMP and wild-type mice were castrated or sham-castrated at 9 wk of age and 
sacrificed 1 wk later. The expression of CMO-I and CMO-II will be measured in the liver, 
prostate, duodenum, and adrenals. We also have sacrificed mice from our aging CMO-I KO, 
CMO-II KO, and wild-type mice colonies to investigate the effects of age and sex on the mRNA 
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expression of CMO-I and CMO-II in selected tissues. Male and female mice were sacrificed at 5, 
9, 31, 51, and 71 wk of age. Preliminary analysis suggests that CMO-I and CMO-II are most 
highly expressed before sexual maturity. Preliminary analysis also suggests there is no sex 
difference in the expression of CMO-I or CMO-II. Further analysis of this data is required. 
Lastly, we have sacrificed male TRAMP mice at 9, 15, and 20 wk of age to determine the effects 
of the progression of prostate carcinogenesis on the mRNA expression of the carotenoid 
cleavage enzymes. At nine wk of age, most mice had normal prostate tissue, but by 15 wk of age, 
neoplasia was apparent in the prostate of these mice. The 20 wk time point has not yet been 
evaluated, but we expect that some 20 wk old TRAMP mice will have developed prostate tumors. 
The expression data has not yet been completed. All of the tissues for this proposed study have 
been collected. Further analysis is necessary to investigate mediating factors on the tissue 
expression of CMO-I and CMO-II. 
 Lastly, we propose further investigation of the phenotypical characteristics of CMO-I KO 
and CMO-II KO mice. Because these knock-out mouse models are new, very few papers have 
been published using these models. Preliminary evidence suggests alterations in lipid metabolism 
in both mouse models and alterations in organ weights needs to be further investigated. We will 
measure liver lipids using the Folch method, serum lipids by colorimetric assay, and genes for 
lipid metabolizing enzymes by RT-PCR. We have reported that female CMO-I KO mice have 
reduced uterus weights. This might suggest alterations in estrogen production in these mice. 
Serum estrogen levels and estrogen metabolizing genes should be investigated. Lastly, we have 
reported that CMO-II KO mice have enlarged spleens. We have histology slides prepared of a 
portion of each spleen from our CMO-II KO mice from previous studies. Additionally, we 
collected tail snip blood smears to look at erythrocyte morphology all of our mouse models. 
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Overall, the phenotype of CMO-I KO and CMO-II KO mice may impact study outcomes, 
therefore further characterization of these models is critical. 
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